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CHAPTER 1
INHERITED AND ACQUIRED RISK FACTORS FOR VENOUS 
THROMBOEMBOLISM
1.1 SUMMARY
1.1.1 Venous thromboembolism (VTE) remains an important cause of morbidity and 
mortality, with well-recognised inherited and acquired risk factors. Women are 
particularly at risk of this condition because of pregnancy, the use of combined oral 
contraceptive pills, and hormone replacement therapy. A number of long-term sequelae 
may occur following an episode of VTE in women, such as development of the post- 
thrombotic syndrome, restriction of future contraceptive choice, bleeding events related 
to anticoagulants, and recurrence of thrombosis. In recent years there has been a 
marked increase in our understanding of genetic risk factors important for the 
development of VTE, and of their interaction with acquired risks. In particular, the 
description of the factor V Leiden and (more recently) prothrombin 202 lOA mutations 
have highlighted common genetic variations that are associated with a modest 
increased risk of thromboembolism. These genetic mutations may also be associated 
with other conditions that are associated with coagulation activation, such as 
preeclampsia. Thrombophilia is a rapidly expanding and complex field, and 
undoubtedly new abnormalities will be described within the next few years.
1.2 INTRODUCTION
1.2.1 Venous Thromboembolism (VTE) is a common condition, particularly in women 
where pregnancy, the combined oral contraceptive pill (COCP) and hormone 
replacement therapy (HRT) are recognised risk factors. In particular, recent publicity 
surrounding the risk of VTE in users of third generation combined oral contraceptives 
(1-3) and users of HRT (4-7), together with an increased number of deaths from 
pulmonary embolism during pregiancy (8), has rendered this an important area of 
research.
1.2.2 It has been reported that between the ages of 15-39, women have a five-fold 
higher risk of experiencing an episode of VTE compared with arterial thrombosis (9). 
Women aged 15-24 years have a reported annual incidence of VTE of 0.2 per 1000; 
between the ages of 25-39 years, this rises to 0.4 per 1000 per year; and between 40-54 
years to 0.74 per 1000 per year (9). These figures compare with annual incidences of 
acute myocardial infarction in women of (for the same age categories) 0.007, 0,19 and 
1.76 (9).
1.2.3 VTE is associated not only with mortality from pulmonary embolism, but also 
significant morbidity, including complications of therapy for VTE, recurrence of 
thrombosis, development of the post-thrombotic syndrome, and reproductive issues 
(pregnancy, restriction of future contraceptive choice). Anticoagulants are associated 
with several potential risks. Bleeding events are increased in patients on heparin and 
those on warfarin. The incidence of major bleeding events in those prescribed warfarin 
is estimated at around 2% per year (10,11). The incidence of fatal bleeding events 
appears less than 1% per year (10,11). Prolonged heparin therapy is also associated
with the development of osteoporosis, which appears to occur commonly, although 
clinical fractures appear uncommon (<5%) (12-15). Heparin-induced 
thrombocytopaenia is a serious condition, paradoxically associated with venous and / or 
arterial thrombosis (16). It is an uncommon complication of heparin therapy that relates 
to the development of antibodies to the heparin-platelet factor 4 complex (16,17).
1.2.4 Young women who suffer an episode of VTE have many years to develop the 
post-thrombotic syndrome (PTS). This syndrome consists of continuing or developing 
symptoms and signs in the previously thrombosed leg, such aS pain, swelling, 
discoloration, varicose veins, eczema, and ulceration. It is likely to relate to venous 
valvular damage with resultant venous hypertension following the episode of 
thrombosis, and appears to increase in incidence as time from thrombotic event 
increases (18). Published data on the prevalence of PTS in unselected groups of patients 
with previous VTE suggest it is a common clinical problem (19-21). However, there 
are few data on the prevalence of this condition in young women.
:
1.2.5 There are no data to assess the possible influence of a previous episode of VTE on 
future contraceptive choice, the decision to have future pregnancies, or access to 
hormone replacement therapy. Most family planning physicians would advise against 
the use of combined oral contraceptives in women with a history o f VTE, since these 
preparations are associated with an increased risk of VTE (1-3,22). Some women may
opt for less reliable forms of contraception with the risk of unplanned pregnancies,
■■which in turn are associated with an increased thrombotic risk. Others may decide that 
they do not wish to risk recurrence of VTE through future pregnancy, and choose 
sterilisation, or vasectomy in their partner. In the longer term, women with a previous
episode of VTE may face difficulties with access to hormone replacement therapy due 
to its association with VTE. This aspect of the long-term effects of VTE has not been
■iiexplored.
1.3 NORMAL HAEMOSTASIS
In order to understand possible mechanisms of thrombosis, a brief outline of the 
coagulation cascade and natural anticoagulant pathways is given below.
1.3.1 The Coagulation Cascade
1.3.1.1 Virchow’s triad states that thrombosis may occur as a result of local 
abnormalities in the vessel wall, blood stasis, or changes in the composition of blood 
favouring thrombus formation. There has recently been a tremendous amount of 
research in elucidating the causes of the third part of this triad. The coagulation cascade 
consists of a series of enzymatic reactions whose primary goal is the production of 
fibrin and platelet activation. These enzymatic reactions occur on the surface of 
platelets, which form a primary haemostatic plug at the site of tissue damage. Platelets 
adhere to subendothelium via binding of Von Willebrand factor to the platelet 
glycoprotein Ib-V-IX complex (reviewed in (23)). Platelet-platelet interaction is 
achieved by fibrinogen binding to the Ilb-IIIa platelet glycoprotein. Central to the 
coagulation cascade is the generation of thrombin. Much research has been directed 
toward understanding the initiation of the coagulation cascade in-vivo. It is now 
generally accepted that the extrinsic pathway (involving tissue factor and FVII) is the 
principal mechanism for initiation of coagulation activation and that the contact system 
may contribute very little to the initiation of this process (reviewed in (24) and (25)). 
The principal role of the contact pathway is the amplification of the coagulation process 
following initiation by the extrinsic pathway. Tissue factor, (TF; also known as
thromboplastin or CD 142), the physiologic initiator of blood coagulation, is an integral 
membrane protein found on the surface of a variety of cell types normally located 
outside the vasculature (26), TF is expressed particularly by macrophages and smooth 
muscle cells at sites of atheroma and is likely to be of prime importance in the 
thrombotic process observed in unstable angina (27) and myocardial infarction (28). It 
has recently been demonstrated that vascular smooth muscle cells may be stimulated to 
produce TF which is identified free (although transiently) at the cell surface, in larger 
pools encrypted at the cell surface, and also intracellularly (29). It is hypothesised that 
the relatively short-lived surface expression of TF may be critical for limiting the 
thrombotic potential of intact cells whereas the encrypted surface and intracellular 
pools may provide a rich source of TF under conditions associated with cellular 
damage, such as during atherosclerotic plaque rupture (29). In response to vascular 
injury or thrombotic stimuli, TF binds F VII or F Vila, enhancing its enzymatic activity 
considerably (26). This in turn generates FXa and thrombin; thrombin generation 
cleaves the serine proteases F Villa and FVa from their zymogens FVIII and FV 
respectively. The TF-FVIIa complex also cleaves FIXa from FIX; after generation of 
thrombin and FVIIIa, the FIXa-F.VIIIa complex (tenase complex) may generate further 
thi'ombin via liberation of FXa (via the prothrombinase complex). The generation of 
thrombin appears central to the regulation of haemostasis, since it may both potentiate 
its own production (by cleavage of FVIIIa and FVa) at sites of tissue damage, and 
downregulate production of further thrombin at sites distant from tissue damage (via 
activation of the protein C anticoagulant pathway) (figure 1.1).
1.3.2 Natural Anticoagulants
1.3.2.1 The natural anticoagulants antithrombin, protein C and protein S are of prime 
importance in limitation of thrombosis to sites of tissue damage in-vivo. Antithrombin 
is a serine protease inhibitor (SERPÏN), synthesised in the liver, which has widespread 
inhibitory activity on the coagulation proteases, particularly thrombin (30). The action 
of antithrombin is accelerated greatly by binding to heparin, which alters its structural 
conformation (30).
1.3.2.2 Protein C is a vitamin K-dependent plasma zymogen of a serine protease, which 
plays a central role in restraining the coagulation cascade (31 ). The known components 
of the protein C anticoagulant pathway are thrombomodulin, which, in complex with 
thrombin, activates the plasma zymogen protein C, to the anticoagulant activated 
protein C (APC) (32). ARC forms a complex with plasma protein S, which assembles 
on membrane surfaces to inactivate factors Va and Villa (32). Recently, a new protein 
C receptor has been identified on the surface of endothelial cells (the endothelial cell 
protein C receptor, EPCR) which appears to augment protein C activation (32). The 
vascular distribution of the EPCR is such that it appears in high concentration in large 
arterial vessels and lower concentrations in the microvasculature (32). The precise role 
of the EPCR, and the reason for its distribution, remain to be demonstrated.
1.3.2.3 Protein S is also a vitamin K-dependent protein that originates predominantly 
from hepatocytes (33). It is a cofactor for APC. In the circulation 60% of protein S is 
associated with C4b-binding protein, the resulting complexes being devoid of APC 
cofactor activity. The remaining free protein S has cofactor activity for APC. FVa 
inactivation by APC occurs in a biphasic reaction, with rapid cleavage at Arg 506
followed by slower cleavage at Arg 306. The first cleavage only partially affects FVa 
activity, whereas full inactivation occurs after the second cleavage at Arg 306. It 
appears that protein S predominantly stimulates APC mediated cleavage at the second 
site (Arg 306) (33). FVIIIa inactivation by APC is increased by both protein S and FV 
(but not FVa), the two proteins acting synergistically as cofactors for the reaction (33).
1.3.2.4 Tissue factor pathway inhibitor (TFPI) is the major inhibitor of the tissue factor- 
FVIIa initiation of coagulation. TFPI is synthesised predominantly in vascular 
endothelium and has a complex distribution (34). A major pool of TFPI (50-80% of the 
total intravascular pool) is normally bound to the vessel wall, although it may be 
released into plasma following injection of heparin (34). The remaining TFPI pool 
circulates predominantly (-80%) in association with lipoproteins (34).
1.3.3 Markers of Coagulation Activation
1.3.3.1 Coagulation activation peptides are released from their zymogen molecules but, 
in contrast to the corresponding enzyme, they have a relatively longer half-life and are 
therefore easier to measure. This makes it possible to study coagulation activation in- 
vivo. The most extensively studied activation peptides are prothrombin fragment 1+2, 
fibrinopeptide A and D-Dimers (fibrin and fibrinogen degradation products). 
Prothrombin fragments 1+2 provide information concerning the amount of thrombin 
generated whereas fibrinopeptide A indicates the extent to which free thrombin exerts 
its activity on fibrinogen (35). D-Dimers represent activation of the fibrinolytic system 
and are particularly useful in the exclusion of venous thromboembolism (36-38).
10
1.4 RISK FACTORS FOR VTE (TABLE 1.1)
1.4.1 Inherited Risk Factors for VTE 
Antithrombin, Protein C and Protein S deficiency
1.4.1.1 Until relatively recently, established thrombophilic abnormalities were found 
infrequently in those with VTE (table 1.2). For example, collectively deficiencies of the 
natural anticoagulants antithrombin, protein C or protein S are found in around 5% of 
patients with a first episode of VTE, although this figure increases in those with 
recurrent events (39). Mutations affecting the antithrombin gene result in either type I 
or type II deficiencies (30). Type I antithrombin deficiency is a quantitative deficiency 
with reduction to approximately 50% of antigen and activity levels. In type II 
deficiencies, the total antigen level is normal (or near nonnal) with a reduction in 
activity level. This may be caused by mutations that produce variants with functional 
defects primarily affecting the heparin binding site or the reactive site (30). Type I 
antithrombin deficiency appears rare in the healthy population. In a study of blood 
donors in the West of Scotland type I antithrombin deficiency was detected in around 
1/5000 individuals (40). Type II antithrombin deficiency was detected in 1.45/1000 
(40).
1.4.1.2 More than 160 mutations have been identified in the protein C gene (reviewed 
in (31)). Each mutation leads to absent or defective protein C and therefore type I #
(quantitative) and type II (functional) defects are observed. Protein C deficiency 
appears not uncommon in the general population, estimated at approximately 1/500 
individuals (41,42). Deficiency of protein S is divided into three subtypes: type I (low 
total and free protein S), type II (nonnal free protein S with reduced APC cofactor 
activity), and type III (low free protein S with nonnal or near normal total protein S) Ï
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(33). Sixty-nine mutations have been associated with type 1 protein S deficiency (33). 
Mutations which produce a type III phenotype appear to influence protein S binding to 
C4b-binding protein (33). Protein S levels are also lower during pregnancy (43) and in 
users of the combined oral contraceptive pill (44). Currently the prevalence of protein S 
deficiency in the general population is unknown.
1.4.1.3 The vast majority of individuals who are identified with deficiencies of 
antithiombin, protein C or protein S are heterozygous for a genetic mutation in the 
relevant gene. Deficiencies of antithrombin, protein C and protein S are inherited in an 
autosomal dominant pattern, such that the offspring of an affected parent have a 50% 
chance of inheritance. Homozygous deficiencies are rare. Homozygous antithrombin 
deficiency usually results in either fetal death or such severe thrombotic manifestations 
that death occurs early in childhood (9). Homozygous deficiencies of protein C or 
protein S are rarely reported and generally associated with a severe thrombotic diathesis 
which requires lifelong anticoagulation, sometimes with regular protein C or protein S 
replacement (45-51).
Activated Protein C Resistance and Factor Vsene Mutations 
\A. 1.4 In 1994, Dahlback found that a significant proportion (around 20%) of patients 
with a first episode of VTE demonstrated a poor anticoagulant response to activated 
protein C added in-vitro to their plasma (APC resistance) (52). Bertina and colleagues 
subsequently demonstrated that such patients had a single point mutation in the gene 
encoding coagulation factor V (factor V Leiden, FVL) (53). This mutation results in an 
Arg Gin substitution at amino acid position 506 of the factor V protein. Factor V is 
converted to the active cofactor. Va, during assembly of the protlirombinase complex.
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Generation of thrombin is limited by cleavage of factor Va by APC at Arg 506, 
followed by cleavage at Arg 306 and Arg 679 (54). Bertina showed that the mutated 
factor Va was relatively resistânt to degradation by APC (53). Individuals with FVL, 
even if asymptomatic for VTE, appear to have excessive generation of thrombin as 
evidenced by elevated markers of coagulation activation (55,56) and consequently a 
relative thrombotic tendency.
1.4.1.5 The APC sensitivity ratio (the ratio of the APTT performed in the presence and 
absence of exogenously added APC) can be used as a screening test for the FVL 
mutation (57). However, the APC sensitivity ratio cannot be used to identify those 
carrying the mutation if the patient is on oral anticoagulants or heparin, or if the patient 
has a lupus anticoagulant / elevated anticardiolipin antibodies (57). In these patients, a 
modified APC test using plasma depleted of coagulation factor V must be used to
screen for FVL. The unmodified APC test is also unreliable during pregnancy (58) or in 
other situations where plasma FVIII is elevated. Acquired APC resistance (an abnormal 
umnodified APC sensitivity ratio in the absence of the FVL mutation) is seen variably 
during pregnancy (43,58), in those vrith lupus anticoagulant activity (59) and in those 
on the combined oral contraceptive (60). It has recently been reported that users of 
hormone replacement therapy have lower mean APC-sensitivity ratios compared with 
post-menopausal non-users (61). It had been noted that there was quite marked 
variability in APC resistance ratios in those with the FVL mutation, which was 
considered to be related to variations in levels of FVIIIc. However, recent research has 
identified a factor V genetic polymorphism (the HR2 haplotype) which appears to 
contribute to the phenotype of APC resistance (62). Individuals who are doubly 
heterozygous for both the FVL mutation and the HR2 haplotype appear to have
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consistently lower APC sensitivity ratios than individuals with FVL alone (62). This 
may be clinically significant, since the risk of VTE appears to increase as the APC 
sensitivity ratio decreases (63). Very recently, a new mutation in the factor V gene has 
been described which is associated with both APC resistance (Ai'g 306 -> Thr, factor V 
Cambridge) and an increased risk of VTE (64). However, this mutation appears very 
rare in thrombotic cohorts (1/602 patients with an episode of VTE in the study by 
Williamson et al (64)), and as such it is not included in thrombophilia screening in most 
thrombosis centres.
1.4.1.6 There have been a considerable number of studies that have confirmed that 
individuals with the FVL mutation are at increased risk of VTE (reviewed in (39)). The 
risk of VTE appears increased 5-10 fold in those heterozygous for the mutation and 
approximately 80 fold in homozygotes (65). Those homozygous for FVL may 
experience thrombosis at a younger age than heterozygotes (65). FVL shows a marked 
variation in prevalence within different populations, being clearly centred in Europe 
and, with a few exceptions, relatively rare outside Europe and North America (66). For 
example, in the UK the prevalence of heterozygous FVL is estimated at 3-5% of the 
general population. A similar figure is found in Germany. In Greece and Sweden the 
prevalence is much higher, approaching 12% in some areas. In South East Asia it 
appears much lower (<1%) and it is almost unknown in Africa. Homozygotes are 
uncommon, though not rare, occurring in approximately 0.2% of healthy individuals in 
Germany (66).
1.4.1.7 The FVL mutation has also been studied as a candidate risk factor for arterial 
thrombosis. However, a relationship to arterial disease appears less well established.
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Some researchers have demonstrated an association between FVL and neonatal, 
childhood and juvenile (<50 years) stroke (67-72). However, not all have found such an 
association (73,74). FVL has not been established as a risk factor for stroke or 
myocardial infarction in unselected adult populations (55,75-82). Rather, most reports 
appear to highlight a risk in selected adult groups, such as young female smokers 
(83,84).
The Prothrombin 20210 G~~>A Gene Mutation
1.4.1.8 In November 1996, Poort et al described a common variation in the 
prothrombin gene that was found in 6% of Dutch patients who presented with a first 
episode of VTE and in 2% of healthy controls (85). Researchers in other countries have 
confirmed these findings (86-91). This mutation, a result of a G to A substitution at 
position 20210 of the 3' untranslated region of the gene, is associated with elevated 
mean plasma prothrombin levels. The precise mechanism for the elevation of 
prothrombin levels, or indeed for the increased risk of VTE, is as yet unknown. One 
study has reported that markers of coagulation activation (prothrombin fragments F1 + 
F2) in carriers of the prothrombin variant are not higher than in controls, although 
endogenous thrombin potential was reportedly higher (92). The prothrombin 20210A 
mutation has been reported in 1.2-2.6% of the healthy population in the UK. (74,87,88). 
It appears to increase the risk of VTE around 2-4 fold, somewhat less than that posed 
by FVL. Since both FVL and the prothrombin mutations are not uncommon, 
individuals with both mutations are occasionally found and appear to have a 
significantly higher thrombotic risk than those with either mutation alone (93-95).
There is emerging evidence that the prothrombin mutation may also be a risk factor for 
arterial thrombosis in adults, again in selected patient groups (84,86,96). In particular, a
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recent large study of selected patients with juvenile stroke (predominantly those aged 
15-50 years) has demonstrated a significantly increased risk of stroke in carriers of the 
prothrombin G~>A mutation (97). However, further research is required in this area 
before widespread screening for this mutation is undertaken in those with arterial 
disease.
1.4.1.9 There are cun ently few data on the racial prevalence of the prothrombin 
mutation, although a recent study has suggested a very low prevalence in non- 
Caucasians (98). It seems clear that this mutation is not uncommon in those with VTE 
and many thrombosis centres now test for this as part of first line investigation of 
possible thrombophilia. Unlike the FVL mutation, which can be detected using the 
APC sensitivity ratio, there is currently no screening test for the prothrombin gene 
mutation, and hence detection relies upon polymerase chain reaction techniques.
1.4.2 Mixed Genetic and Acquired Risk Factors for VTE 
Hvperhomocvsteinaemia
1.4.2.1 Elevation of plasma homocysteine appears to confer an increased risk of both 
venous and arterial thrombosis (99-107). Two major pathways regulate Homocysteine 
metabolism: remethylation to methionine, and trans-sulfuration to cysteine (reviewed in 
(107) (figure 1.2). The conversion of homocysteine to methionine occurs through a 
vitamin B 12-dependent remethylation step involving 5-methyltetrahydrofolate (107). 5- 
methyltetrahydrofolate, the main form of circulating folate, is formed from 5,10 
methylenetetrahydrofolate by the enzyme methylenetetrahydrofolate reductase 
(MTHFR) (107). In the trans-sulfuration pathway, homocysteine is converted to 
cystathionine in a reaction which is catalysed by the enzyme cystathionine beta
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synthase (CBS) (107). Recently, Frosst described a C-^ T mutation at position 677 in 
the MTHFR gene, which is associated with a reduced enzyme activity and enzymic 
thermolability (108). Individuals with the homozygous C-^T MTHFR (thermolabile) 
variant have higher homocysteine levels for an equivalent folate level compared to wild 
type MTHFR subjects (109-111). Subjects homozygous for the C-^T MTHFR variant 
that are folate deficient have significantly elevated fasting levels of homocysteine and 
may be at increased risk of both VTE and arterial thrombosis (110). Homozygosity for 
the variant MTHFR gene is common in the general population (11% in the UK) (112). 
However, the majority of studies which have examined the prevalence of homozygous 
C ^T  MTHFR subjects with VTE have failed to demonstrate an increased risk, 
suggesting that folate deficiency may be an important interacting factor in those who 
develop VTE (113,114).
1.4.3 Other Coagulation Abnormalities Predisposing to VTE
1.4.3.1 A considerable proportion (10-15%) of individuals that present with VTE are 
noted to have persistently elevated levels of plasma FVIII (115). Elevation of FVIII 
(levels >150 iu/dl) is associated with a 4-5 fold increase in risk of VTE (115).
However, FVIII gene studies have failed to demonstrate an associated mutation (116). 
This elevation in FVIII appears independent of underlying inflammation (117). 
Abnormalities of the thr ombomodulin gene have also been repotted in some patients 
with VTE; however, such defects appear rare in thrombotic cohorts (118). 
Abnormalities of the fibrinolytic pathway, such as plasminogen deficiency, are 
considered by some researchers to be a risk for development of VTE (reviewed in 
(119)). However, plasminogen deficiency has been reported as a not uncommon finding 
in healthy individuals who are thrombosis-free, and many do not regard this as a
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significant thrombotic risk factor (119,120).
1.4.4 Acquired Risk Factors for VTE 
Antiphospholipid Syndrome
1.4,4.1 The antiphospholipid syndrome (APS) may be defined as the occurrence of 
thrombosis (venous and / or arterial), recurrent (3 or more) miscarriage and / or 
thrombocytopaenia in association with evidence of a lupus anticoagulant or 
anticardiolipin antibody (reviewed in (121)). The term antiphospholipid antibody refers 
both to a lupus anticoagulant or the presence of an anticardiolipin antibody. The APS 
may be primary, or occur in association with connective tissue disorders, 
lymphoproliferative disorders, infection or complicate drug therapy (121). Despite their 
in-vivo thrombotic tendency, lupus anticoagulants act as in-vitro coagulation inhibitors, 
with detection being dependent upon prolongation of a clotting time with 
demonstration of inhibitory activity on mixing tests, and complete or partial correction 
of clotting times with addition of phospholipid (122). The most widely used tests for 
detection of lupus anticoagulants are the activated partial thromboplastin time, dilute 
Russell’s viper venom time (DRW T), and kaolin clotting time (122). Anticardiolipin 
antibodies (ACA) are detected using ELISA techniques. A recent epidemiological 
study demonstrated that individuals with moderate or high (>40 U) titre IgG ACA 
appear at particularly increased risk of thrombotic events compared to those with lower 
titres or with other classes of ACA (123). Antiphospholipid antibodies (lupus 
anticoagulant and / or anticardiolipin antibodies) have complex effects on haemostasis, 
binding to beta-2-glycoprotein I (p2-Gpl) (124), prothrombin (125,126), protein C 
(127-129), protein S (125,129), thrombomodulin (130), endothelium (131-133) and 
platelets (134). Clearly antiphospholipid antibodies are heterogeneous, with no single
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mechanism of thrombosis proven. Antiphospholipid antibodies may be transient, and 
persistently positive tests must be demonstrated in an appropriate clinical setting in 
order to make a diagnosis of antiphospholipid syndrome. Guidelines on the 
investigation and management of the antiphospholipid syndrome are in preparation 
(135).
Presnancv
1.4.4.2 In women, it has long been recognised that pregnancy is a risk factor for VTE. 
The recent Report on Confidential Enquiries into Maternal Deaths in the UK (1998) has 
highlighted death from pulmonary embolism as the major cause of maternal mortality 
in the United Kingdom (8). VTE associated with pregnancy will be considered in 
greater detail in Chapters three and four.
Combined oral contraceptives
1.4.4.3 Combined oral contraceptive pills (COCP) were reported as a possible risk 
factor for VTE in the mid-1960’s. Recent research has identified that the newer third- 
generation preparations (those containing the progestogens desogestrel or gestodene) 
appear to pose a greater risk of VTE than earlier second-generation preparations (those 
containing the progestogen levonorgestrel) (1-3). The increased risk of VTE in users of 
second generation COCP is reported at 3.5 (95% Cl 2.6-4.7), compared with 9.1 (4.9- 
17) for desogestrel-containing preparations and 9.1 (4.9-16.7) for gestodene-containing 
preparations (1). Women with a body mass index (BMI) greater than 25 kg/m^ appear 
to have a higher risk of COC related VTE than those with a lower BMI (2). Third- 
generation COCP, like second generation preparations, contain 30-35 pg
ethinyloestradiol. They have been reported to have significant effects on plasma levels
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of natural anticoagulants, procoagulants and the fibrinolytic system (table 1.3) (136). 
These effects, if considered collectively, appear to promote a relative thrombotic 
tendency, and may explain the observed increased risk of VTE. Doubt was cast on data 
showing a higher risk of VTE in users of third-generation COCP compared to second- 
generation pills, since there appeared to be no plausible physiological explanation for 
the clinical findings. However, recent research has shown that third-generation COCP 
appear to produce a significant degree of resistance to activated protein C (comparable 
to that seen in heterozygous carriers of the factor V Leiden mutation) (60), providing a 
possible mechanism for these clinical observations.
Hormone replacement therapy
1.4.4.4 Hormone replacement therapy (HRT) has been demonstrated to have significant 
effects on lipid metabolism, with a reduction in LDL-cholesterol and increase in HDL- 
cholesterol (137). Users of HRT (both oestrogen-only and oestrogen-progestogen 
preparations) also experience an overall reduction in plasma fibrinogen concentration 
(137). These effects may explain, at least in part, the cardioprotective effect that has 
been demonstrated in users. Users of HRT have also been demonstrated to have 
significantly lower levels of antithrombin and protein S, and increased levels of 
coagulation activation markers (137). HRT has recently been reported to be a risk 
factor for VTE (4-7). The relative risk appears to be around 2-3 fold in current users. 
Estimates place the extra risk of VTE in women using HRT at around 1 event per 5000 
users per year (4,7). The mechanism for an increased risk of VTE is unknown, although 
the effects on levels of natural anticoagulants may be important. In considering the use 
of HRT, however, the relatively small risk of VTE should be weighed against the 
potential benefits, such as a reduction in cardiovascular events and osteoporosis,
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particularly as VTE has a low mortality compared with ischaemic heart disease.
Surserv
1.4.4.5 Surgery and immobility are well-recognised periods of increased risk of VTE 
(138,139). In particular, orthopaedic and neurosurgery are considered high-risk for 
subsequent development of VTE (138). There are considerable data demonstrating that 
low molecular weight heparins (LMWH) may significantly reduce the risk of VTE in 
such high-risk patients with no apparent increased risk of bleeding compared to V 
unffactionated heparins (reviewed in (138)). However, despite thromboprophylaxis 
with LMWH, some 15-20% of such individuals develop VTE (reviewed in (140)).
Serious medical illness
1.4.4.6 Other hospital inpatients, for example those on medical wards with cardiac 
failure, nephrotic syndrome or infection are also at increased risk of VTE (141). Most 
hospitals now have protocols to help prevent this complication, the development of 
which are aided by publications such as those by the Scottish Intercollegiate Guidelines 
Network (SIGN) (142).
Malisnancv
1.4.4.7 Interest has recently been given to the observation that individuals with cancer 
are at increased risk of VTE. VTE may be the presenting feature of a variety of 
malignancies, and not uncommonly develops in those with clinically overt cancer 
(143). It is also recognised that patients with cancer are at increased risk of 
postoperative or immobility-related VTE compared to postoperative or immobilised 
patients without cancer (144). Data suggest that cancer cells may express both tissue
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factor and cancer procoagulant, a cysteine protease which may directly activate FX 
(reviewed in (143)). In addition, fibrinogen levels and platelet count are elevated in 30- 
40% of patients with cancer (143). Coagulation activation markers, such as 
prothrombin fragments 1+2, thiombin-antithiombin complexes and D-Dimers are also 
elevated in a significant proportion of patients with cancer (143). A number of studies 
have demonstrated that individuals who present with objectively confirmed VTE are 
significantly more likely to develop cancer within 6-12 months than those who present 
with possible VTE subsequently excluded by objective testing (reviewed in (145)). It 
has also been shown that patients who present with idiopathic VTE are significantly 
more likely to develop cancer (around 10%) than those in whom VTE is associated 
with a recognised precipitant (145). Controversy surrounds the question of screening 
for occult malignancy in those who present with idiopathic VTE.
1.4.4.8 There is current interest on the influence of low molecular weight heparins on 
tumour cell biology (146). LMWH have been demonstrated to prolong survival in 
subjects with cancer compared to unffactionated heparins (144), stimulating interest on 
the effect of LMWH on tmnour growth and development. Tissue factor expression by 
tumour cells may be involved in tumour angiogenesis (147), providing a possible 
mechanism through which anticoagulant therapy may influence tumour growth.
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1.5 GENETIC - ENVIRONMENTAL INTERACTIONS IN THE 
DEVELOPMENT OF VTE
1.5.1 It is apparent that most subjects with inherited thrombophilia develop VTE only 
when additional prothrombotic triggers are posed. In certain situations the combination 
of inlierited thrombopliilia and an additional factor appear to synergistically increase 
the risk of VTE. For example, it is known that the FVL mutation increases the risk of 
VTE approximately 5-10 fold (65). The combined oral contraceptive pill (COCP) is
who are also carriers of the FVL mutation appear to have an increased risk of VTE of
generation oral contraceptive pills (149). A recent study has shown that COCP induces 
APC resistance in subjects who do not possess FVL, and potentiates the degree of APC 
resistance in those with FVL, thus providing a biological explanation for these clinical 
observations (60). It is as yet unknown if there is a similar synergistic effect in users of 
hormone replacement therapy who are carriers of FVL. It is also recognised that 
individuals with deficiencies of natural anticoagulants are at increased risk of VTE if 
taking the COCP (150). At present there are ho data regarding a possible interaction 
between the recently described prothrombin gene variant, the COCP or hormone 
replacement therapy.
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associated with an approximate four-fold increased risk of VTE (1-3). Users of COCP
■ ”5:
around 35 fold (148). The risk is even higher in those with FVL who are users of third
1.
1.6 THROMBOPHILIA AND ADVERSE PREGNANCY OUTCOME
1.6.1 In addition to the well-documented increase in risk of VTE, thrombophilic 
abnormalities have also been examined as possible risk factors for the development of 
adverse pregnancy outcomes, such as gestational hypertension, preeclampsia, placental 
abruption and fetal loss. Several studies have reported that women with the FVL 
mutation are at increased risk of severe preeclampsia (151-155). The MTHFR TT 
(thermolabile) genotype may also increase the risk of preeclampsia (152,156), perhaps 
because pregnancy may be accompanied by folate deficiency, which could lead to the 
development of elevated plasma homocysteine. There are also data indicating that FVL 
and the prothrombin mutation are risk factors for the development of gestational 
hypertension with or without proteinuria (157). A recent study, in addition to 
demonstrating a risk of severe preeclampsia, showed an increased risk of placental 
abruption in carriers of FVL and the prothrombin mutation, although the numbers were 
small (155). There is some evidence that natural anticoagulant deficiencies, and FVL, 
may be associated with fetal loss (158,159).
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1.7 CONCLUSIONS
1.7.1 VTE poses a serious health risk, particularly to women who are at increased risk 
by virtue of pregnancy and hormonal preparations. Thrombophilic abnormalities are 
not uncommon in the general population and in some cases may interact synergistically 
with acquired risk factors to considerably heighten the risk of VTE. Since 
thrombophilic abnonnalities are relatively common, it is increasingly recognised that 
those at greatest risk of VTE possess either multiple thrombophilias (such as both FVL 
and natural anticoagulant deficiencies (160-162), or FVL and prothrombin mutations 
(94,95)) or those with single thrombophilias in risk situations.
.1
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Table 1.1: Inherited and Acquired Risk Factors for VTE ■1
Inherited factors Inherited / Acquired Acquired factors ■i
Antithrombin deficiency Hyperhomocysteinaemia ^ Combined oral contraceptives
Protein C deficiency Elevated FVlll Hormone replacement therapy Ïs
Protein S deficiency Pregnancy 1::
Factor V Leiden Surgery
Prothrombin 202 lOA Immobility
Cancer
Medical illness 1^'
Antiphospholipid syndrome
 ^phenotypic expression appears to be a result of genetic susceptibility and acquired 
vitamin deficiency
in subjects with VTE, it is uncertain if elevated FVlll is inherited or acquired
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Table 1.2: Prevalence of Inherited Thrombophilia in Consecutive Subjects with a
First Episode of VTE and in the General Population [adapted from Lane et al 
(39)1
Thrombophilia General population (%) Consecutive patients with 
first VTE (%)
Antithrombin deficiency 0.02 1
Protein C deficiency 0.2 3
Protein S deficiency ? 1-2
Factor V Leiden 2.2 20
Prothrombin 202 lOA 2.2 6-8
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Table 1.3: Influence of Third Generation, Low Oestrogen Combined Oral
Contraceptives on Various Haemostatic Parameters [from Kluft et al (136)].
Haemostatic Parameter Increased Decreased
Natural Anticoagulants heparin cofactor II
protein C
Procoagulants
Profibrinolytics
Antifibrinolytics
protein S (total & free) 
APC ratio 
antithrombin
C4b-BP
Factors I, II, VII, VIII, DC, X,
XI
vWf
plasminogen tissue plasminogen activator
Factor XII
Factor XIII PAI-I
Cl-esterase inhibitor
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Figure 1.1. The Coagulation Cascade and the Protein C (red / blue) Pathway.
XI XIa
\/
Tenase complexTF/Vlla IX IXa
>  \ V illa , Ca PL >  V llliVIII
Prothro nbinase complex
f  >  Xa 
>  Va Ca PL >Vi
FV
Protein S
^  Thrombin A P C ^Prothrombin Protein C
Thrombomodulin
Fibrinogen ^Fibrin
XIa, IXa activated coagulation factors 
Vi, VIHi inactivated coagulation factors 
APC activated protein C 
PL phospholipid 
TF tissue factor
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Figure 1.2, Methionine / Homocysteine metabolism
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CHAPTER! 
H)ENTIFICATION OF RISK FACTORS FOR VENOUS 
THROMBOEMBOLISM IN WOMEN IN THE WEST OF SCOTLAND 
2.1 SUMMARY
2.1.1 Three hundred and twenty-two consecutive women aged 16-70 years who 
presented with symptomatic VTE were studied to determine precipitating factors for 
thrombosis. In 283 women this was a first episode of VTE and in 39 was a recurrent 
event. 187 presented with DVT, 116 with either definite or probable PE, and 19 with 
both DVT and PE. The 18 who died from PE (mean age 59.3 years, SD 11.4, n=18) 
were significantly older than those who survived PE (mean age 50.1 years, SD 14.5, 
n^l 17) {p< 0.005). Pregnancy was the most common precipitating factor for VTE, 
associated with 14% of all events and 33.6% of events under 40 years. Intravenous drug 
abuse was also a common trigger for VTE, associated with 13.7% of all objectively 
confirmed events and 33.6% of events in women under 40 years. A large number of 
clinically diagnosed DVT associated with IVDA were documented, suggesting that 
IVDA may be the most common triggering factor for DVT in our region. None of the 
IVDA cohort presented with symptomatic PE. Cancer, particularly of breast, colorectal, 
and lung, was also commonly associated with VTE, detected in 12.8% of the entire 
cohort and almost 25% of those aged over 50 years.
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2.2 INTRODUCTION—     -----
2.3 AIMS
2.3.1 To document risk factors for VTE in a cohort of consecutive females aged 16-70 
years diagnosed with either deep vein thrombosis (DVT) and / or pulmonary embolism 
(PE) and treated at one of two Glasgow hospitals between 1993-1997.
I"t
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2.2.1 Venous thromboembolism (VTE) remains an important cause of morbidity and 
mortality, particularly in women. This relates predominantly to female exposure to risk 
factors for VTE, such as pregnancy, the COCP, and HRT, in addition to other risks 
such as surgery, immobility and cancer. It must be stressed, however, that the absolute 
risk of VTE in pregnancy, or in users of the COCP or HRT, is low, and that in certain 
geographical areas other risk factors for VTE may be important. For example, in our 
area intravenous drug abuse (IVDA) is highly prevalent, with injection into the femoral 
vein a common mode of administration. It is generally acknowledged that such an 
injection technique may constitute a risk for development of deep vein thrombosis and 
/ or pulmonary embolism. The contribution of IVDA to the development of VTE has 
thus far received little attention.
Î
2.4 MATERIALS AND METHODS
2.4.1 Consecutive females aged 16-70 years who had been diagnosed with DVT or PE 
and treated at one of two Glasgow hospitals (Glasgow Royal Infirmary University NHS 
trust or the Southern General NHS Trust) between 1993-1997 were the subject of study. 
Women who developed VTE related to pregnancy were also included, since both 
hospitals have associated maternity units. Subjects were identified using ÏCD9 and
ICDIO (from 1996) coding data obtained from SMRl returns to the local health board.
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Women with DVT or PE related to pregnancy were identified from SMR2 data. Case- 
notes from all subjects were recalled and examined. Information extracted from the 
case-notes included patient demographics, diagnosis, technique used to establish 
diagnosis, and possible risk factors for VTE (see appendix 1). Only patients in whom 
the diagnosis was objectively confimied were included. For the purposes of our 
analysis, the diagnosis of DVT was accepted if confirmed by compression or duplex 
Doppler ultrasound scanning or contrast venography (except in the cases associated 
with IVDA, see below). For PE, we accepted a high probability V/Q scan as definite 
evidence of PE. A diagnosis of probable PE was made where the V/Q scan was of 
intennediate probability and patients were treated with at least six months 
anticoagulation, or cases which were diagnosed on the basis of clinical, ECG, and x-ray 
findings and received six months anticoagulation. The case-note search identified a 
large number of women who were intravenous drug abusers (IVDA) who had 
developed apparent DVT. Many such cases were diagnosed clinically; this data is also 
presented. The case-notes from 41 women could not be located. These patients were 
not included in our analysis.
2.4.2 Statistical techniques
2.4.2.1 Normally distributed patient characteristics were assessed by using the Students 
t-test. p  values are two-tailed.
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2.5 RESULTS
2.5.1 Three hundred and twenty-two women were admitted with an episode of 
objectively confirmed VTE during the study period. In 283 women this was a first 
episode of VTE and in 39 was a recurrent event. 187 presented with DVT, 116 with 
either definite or probable PE, and 19 with both DVT and PE. The mean age of women 
with PE (50.0 years) was significantly higher than those with objectively confirmed 
DVT (41.3 years) (p < 0.0001). However, after excluding all cases of VTE related to 
IVDA, the difference in ages was not statistically significant (mean age of those with 
DVT 47.6 years, mean age of those with PE 50.0 years,/? = NS). Of women with 
clinically isolated DVT, 103 presented with DVT in the left leg, 77 with right leg DVT 
and in 7 cases DVT was bilateral. 68 women had definite PE and 48 probable PE. 18 
(5.5%) died during hospital admission from PE (table 2.1). 11 women were known to 
have subsequently died (5 from cancer, 1 from congestive cardiac failure, 1 from 
respiratory distress syndrome in an IVDA; in the remaining 4 women the cause of death 
was not available). 23 women had a recurrent tlnombosis during the study period. Of 
this 23, thirteen were IVD abusers; 2 others originally presented with idiopathic VTE.
2.5.2 Risk factors for VTE are shown in table 2.2. Twenty-one percent (68/322) of all 
episodes had no identified precipitating factor. Pregnancy was the most frequent 
associated factor, identified in 14% (45/322) of all events. A further 13.7% (44/322) 
were associated with IVDA. Inclusion of all possible cases of DVT (objective and 
clinically diagnosed cases) associated with IVDA increased the total number of events 
related to IVDA to 82, representing 23% (82/360) of all events. Many women with 
possible DVT related to IVDA self-discharged from hospital before an objective test 
could be perfonned, or in some cases the attending clinician felt the diagnosis was
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!obvious and that further confirmatory tests were unnecessary. Of 82 women with 
possible VTE secondaiy to IVDA, all were treated with subcutaneous heparin. Only 2 
were discharged on oral anticoagulants.
2.5.3 Malignancy was a common precipitating factor for VTE: 12.8% (41 women) had 
evidence of malignancy at presentation, or had developed a malignant process within 
twelve months of VTE (this was the case for one patient). Breast carcinoma was the 
most common tumour associated with development of VTE (table 2.3), accounting for 
46% of all malignancies identified. Colorectal (15%) and bronchial (12%) carcinomas 
were the next most frequently identified tumours. Of six cases of VTE identified in 
association with colorectal carcinoma, 4 occurred following surgery for colectomy. The 
prevalence of cancer-related VTE increased with patient age (figure. 2.1): between the 
ages 15-39 years there were no cancer-related VTE events among 130 VTE cases. This 
increased between 40-49 years (3/32, 9%), 50-59 years (15/64, 23%) and 60-70 years 
(23/96,24%).
I
2.5.4 Twenty-one (6.5%) women developed VTE in association with synthetic 
oestrogen containing pills. 5 occurred in users of third (desogestrel or gestodene) 
generation pills, 3 in users of second generation pills, 5 in other oestrogen-containing 
preparations (all Dianette®, an oestrogen- containing preparation combined with an 
antiandrogen rather than a progestogen, used in the treatment of acne and hirsutism), 
and in 8 cases the preparation was not specified. 24/322 (7.5%) women were users of 
HRT at the time of VTE. In addition, two women who developed VTE related to 
surgery were users of HRT, and one woman who developed VTE whilst immobilised 
due to a fractured ankle was on HRT at time of event. In 25/27 cases, the HRT was an
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oral preparation; in 2 cases the preparation was not specified. In most cases the duration 
of use of COCP or HRT was not specified in the case-notes.
2.5.5 Thirty-three (10.2%) women developed VTE within one month of surgery (this 
included 5 who also had cancer and 2 who were users of HRT). 10 occuiTed following 
orthopaedic surgery. In 22 (6.8%) women VTE was associated with immobility, 9 of 
which were related to plaster cast immobilisation of the lower limbs. 16 (5%) women 
had an associated medical illness predisposing to VTE, the most common of which 
were myocardial infarction / failure (7) and respiratory disease (3). Most women who 
developed VTE related to surgery, immobility or medical illnesses were over 50 years 
old (figure 2.2). Whilst only 4% of women had previous VTE as the only risk factor for 
the present event, 12.1% (39/322) of the entire cohort had previously suffered an 
episode of VTE.
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2.6 DISCUSSION
events (23% of all VTE if clinically diagnosed IVDA events are included). In women 
under 40 years with objectively confirmed VTE (n=131), IVDA accounted for 33.6% 
(44/131) of all events. This compares with 33.6% (44/131) related to pregnancy and
vS;
2.6.1 This analysis of 322 consecutive women aged 16-70 years with objectively
confirmed VTE demonstrates that a recognised precipitating factor for thrombosis was 
present in 79% of all cases. Surprisingly, IVDA was associated with 13.7% ot all
15.3% (20/131) related to COCP in this age group. All women with VTE who were 
IVD abusers developed DVT; none presented with symptomatic PE. Many such women 
self-discharged from hospital early (and in many cases without follow-up), and 
therefore we cannot be certain that a proportion did not subsequently develop PE.
However, this seems unlikely, since none were readmitted to either hospital with PE.
2.6.2 Fifty-four percent (44/82) of DVT associated with IVDA were objectively 
confirmed. In the remainder, the diagnosis was made clinically, or the patient self- 
discharged prior to a radiological examination being performed. There are few data on 
the prevalence of IVDA as a precipitating factor for VTE. Labropoulos et al studied 47 
consecutive patients, who were IVD abusers, presenting with suspected DVT (163).
;DVT was diagnosed by duplex Doppler ultrasound in 63% of limbs. Ten patients had 
.bilateral DVT. The remainder had a variety of diagnoses, such as groin abscess, 
haematoma, arteriovenous fistulae, cellulitis, and false aneurysm. In nine patients no 
diagnosis was reached. It was notable that in this study, 3 patients developed 
symptomatic pulmonaiy embolism. This is in contrast to our cohort, in whom none 
presented with symptomatic PE. £
i
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2.6.3 It was of interest that only 2 women with DVT associated with IVDA were 
treated with oral anticoagulants. In one such patient, warfarin was discontinued after 
only 4 weeks due to poor and erratic compliance with therapy. Amongst clinicians there 
is uncertainty regarding the best way to manage these patients. Problems with 
continued drug abuse, with the risk of vessel puncture whilst on anticoagulants, are 
clearly of concern and mean that at present few such patients are anticoagulated in the 
community. Considering these patients represent a significant proportion of women 
with VTE, studies are needed to determine the correct approach to treatment, since at 
present there are few data on which to base recommendations.
2.6.4 Cancer was identified in 12.8% of all women with VTE. Cancers of the breast 
(46%), colon (15%) and lung (12%) were those most frequently identified in 
association with VTE. The distribution of cancers amongst women with VTE closely 
followed the prevalence of cancers in women generally: data on almost 120 000 women 
with cancer in the UK aged 16-75 years demonstrates breast (26.3%), colorectal 
(13.2%), and lung (11.3%) as the commonest primaiy tumours (164).
2.6.5 Most patients in the cancer related VTE gi'oup had overt cancer at presentation; in 
one woman cancer was diagnosed within several months of presentation with VTE. 
However, we do not know how many women developed cancer after presentation since 
formal follow-up was not undertaken. Monreal recently investigated 832 consecutive 
patients (male and female) admitted with VTE and identified overt cancer at 
presentation in 17.7% (165). Other predisposing risks included surgery (26.5%), 
immobility (20%), previous VTE (13%), COCP / HRT (1%) and pregnancy (1%). In 
addition, screening tests detected cancer in a further 2% during initial hospital
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admission, and in a further 1% during follow-up over several months or years. The 
subsequent development of malignancy appeared significantly more common in those 
with idiopathic versus secondary VTE (165). In Monreal’s study, cancers of the colon, 
breast and lung were the most common primary sites associated with VTE, in keeping 
with our findings. Other studies have supported the idea that those with idiopathic VTE 
are more likely to subsequently present with cancer compared to patients with 
secondary VTE (166-168). However, not all studies have confirmed this (169). 
Screening for occult malignancy in those presenting with VTE has been investigated by 
Barosi who concluded that screening for cancers of the breast and colon in females 
might be worthwhile (170). However, screening is expensive and the natural history of 
the cancers under investigation must be amenable to change. A large Danish study of 
individuals with VTE recently concluded that there was only a small relative risk of 
subsequent development of cancer (171). This study demonstrated that those presenting 
with VTE were more likely to present with cancer in the first 6 months after 
presentation, and that the relative risk of presentation with cancer rapidly declined to 
that that seen in the background population after this period. The authors concluded that 
extensive investigation to detect malignancy was not warranted (171).
2.6.6 In absolute terms, we found that HRT was a slightly more common precipitating 
factor for VTE than the COCP. However, the median age of those in the HRT group 
was significantly higher than in the COCP group, which may partly account for this 
observation. Pregnancy was a common risk factor for development of VTE, accounting 
for 14% of all cases and 33.6% of those < 40 years. Pregnancy will be considered in 
detail in Chapter 3.
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2.6.7 Eighteen women died from PE after admission to hospital. Four deaths occurred 
in women who were known to have cancer and two in association with orthopaedic 
surgery. A further 2 deaths occurred in women with cardiac disease. Seven deaths 
occurred in women without an obvious precipitant. One woman, who presented with 
massive PE associated with hypotension and hypoxia, was treated initially with
events and 33.6% of events in those under 40 years. Cancer, particularly those 
originating from breast, colorectal, or lung, was also commonly associated with VTE, 
detected in 12.8% of the entire cohort and almost 25% of those aged over 50 years. 
Further research is needed, particularly in those with VTE associated with IVDA. Data
1
thrombolysis (tissue plasminogen activator) and survived. All others were treated with 
.intravenous heparin followed by oral anticoagulants. The mean age of women who died 
from PE was compared to those who survived the event. Those who died (mean age
59.3 years, SD 11.4, n=18) were significantly older than those who survived (mean age
50.1 years, SD 14.5, n=l 17) {p< 0.005). A recent study has identified prognostic factors 
in those presenting with acute PE (172). Older age (>70 years), cancer, heart failure and 
chronic obstructive pulmonary disease were identified as significant prognostic factors.
In addition, certain clinical signs on presentation (systolic arterial hypotension, 
tachypnoea, and right ventricular hypokinesia on echocardiography) were also of 
independent prognostic significance.
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2.6.8 In summary, this study of precipitating factors for VTE in women aged 16-70 
years in the West of Scotland has demonstrated that most events have an underlying 
triggering factor. Surprisingly, intravenous drug abuse was identified as a highly 
prevalent risk factor, particularly in women less than 40 years. None of the IVDA 
cohort presented with symptomatic PE. Pregnancy was associated with 14% of all
'i
on this group, to detennine the risk of PE, would help in the design of evidence-based 
management guidelines. II
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Table 2.1 Details of Eighteen Women who Died from Pulmonary Embolism
Age Previous VTE Risk factor(s) Notes on risk factors Additional
information
68 No cancer bronchial carcinoma V/Q confirmed
65 No surgery recent arterial graft 
immobile
Probable PE 
Definite DVT
63 No cancer breast caticer Probable PE 
Definite DVT
68 No nil V/Q confirmed
65 No cancer pancreatic cancer V/Q confirmed
64 No nil Probable PE. 
Definite DVT
64 No surgery 2 days post-op V/Q confinned
70 No medical illness myocardial infarction V/Q confirmed
28 No nil V/Q confirmed
56 No nil V/Q confirmed
38 No surgery internal fixation of leg 
fracture
Post mortem 
diagnosis
65 No nil V/Q confinned
70 No nil V/Q confinned
56 No HRT Premique® Post mortem 
diagnosis
68 No nil Post mortem 
diagnosis
55 No medical illness CCF V/Q confinned
57 No surgery post hip replacement V/Q confinned
48 No cancer bronchial carcinoma V/Q confirmed
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Table 2.2 Risk Factors in 322 Women aged 16-70 years with Objectively 
Diagnosed VTE between 1993-97.
Risk Factor Median age (range) DVT (n) PE(n) Total (%)
Nil 58(17-70) 28 40 68 (21%)
Pregnancy^ 30(19-41) 30 15 45 (14%)
IVDA^ 28 (20-39) 44 0 44(13.7%)
Cancer^ 61 (43-70) 22 19 41 (12.8%)
HRT'^ 56 (37-65) 11 13 24 (7.5%)
COCP 30 (19-44) 11 10 21 (6.5%)
Surgeiy^ 59.5 (22-69) 12 16 28  ^ (8.7%)
Immobility^ 56 (34-69) 11 11 22 (6.8%)
Medical illness^ 64.5 (46-70) 6 10 16 (5%)
Previous VTE*^ 56 (32-69) 12 1 13 (4%)
I,'lr.
1'88
' excludes 5 patients who developed VTE following surgery for cancer 
 ^3 women with VTE related to pregnancy had a previous history of VTE 
 ^ 9 women with VTE related to IVDA had a previous history of VTE 
 ^4 women with VTE related to cancer had a previous history of VTE 
4 women with VTE related to HRT had a previous history of VTE 
 ^4 women with VTE related to surgei^ had a previous history of VTE 
 ^one woman with VTE related to immobility had a previous history of VTE 
 ^one woman with VTE related to medical illness had a previous history of VTE 
* Previous VTE as the only risk factor for current event
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9Table 2.3 Cancers Predisposing to VTE in forty-one Women
Malignancy Number (%)
Breast 19 (46%)
Colorectal 6 (15%)
Lung 5(12%)
Ovary 3(7%)
Unknown Primary 2(5%)
Cervix 1
Uterus 1
Pancreas 1
Cerebral 1
Haematological 1
Bladder 1
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Figure 2.1 Prevalence of Cancer in 322 Consecutive Women aged 16-70 years with 
VTE
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Figure 2.2 Women who Developed VTE Related to Surgery, Immobility or 
Medical Illness by Age-Band.
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CHAPTER 3 
CLINICAL AND THROMBOPHILIC RISK FACTORS IN WOMEN WITH 
VENOUS THROMBOEMBOLISM ASSOCIATED WITH PREGNANCY
3.1 SUMMARY
47
3.1.1 Venous Thromboembolism remains the commonest cause of maternal mortality in
.the United Kingdom. We have conducted a large study (encompassing over 93 000
maternity’s) to determine the incidence of VTE in association with pregnancy, and to 
examine the role of inherited thrombophilia and clinical risk factors for this condition. 
Eighty-seven objectively confirmed VTE events (64 DVT, 23 PE) were recorded at two 
maternity units in the UK between the years 1985-1998 inclusive. The incidence of
I
DVT was 0.68 per 1000 maternity’s (95% Cl 0.51-0.85) with 0.47/1000 occurring in
,the antenatal period (95% Cl 0.33-0.61) and 0.21/1000 in the puerperium (95% Cl
0.12-0.3). The incidence of PE was 0.25 per 1000 maternity’s (95% Cl 0.15-0.35), 
0.1/1000 antenatal (95% Cl 0,04-0.16) and 0.15/1000 in the puerperium (95% Cl 0.07- 
0.22). Of these 87 women, 75 attended for follow-up and thrombophilia screening. The 
prevalence of thrombophilic abnormalities in cases was compared to that obtained in 
over 200 random unselected cord blood controls, and to the prevalence of antithiombin 
deficiency in over 9000 blood donors in our area. Carriers of the factor V Leiden (OR 
4.5, 95% Cl 2.1-14.5) and prothrombin 20210G->A (OR 4.4, 95% Cl 1.246) 
mutations were at increased risk of VTE related to pregnancy. Deficiency of 
antithrombin was associated with a particularly high risk of VTE (OR for type I 
deficiency 282, 95% Cl 31-2532; for type II deficiency OR 28,95% Cl 5.5-142). The 
overall prevalence of thrombophilia in the cohort was 26.7%. The homozygous C677T 
mutation in the MTHFR gene was not associated with an increased risk of VTE (OR
■0.45, 95% CI 0.13-1.58). No women were identified with deficiency of protein S. In
those with the FVL and prothrombin mutations, additional clinical risk factors for VTE
were common. Our study demonstrates that thrombophilic abnormalities not
uncommonly underlie maternal VTE. However, since acquired clinical risk factors for
VTE are common throughout the group, awareness of such risks remains the key to 
.reducing the incidence of maternal thromboembolism. In addition, selective
■llthrombophilia screening in those with a personal or family history of venous
.. .'.T-T
thrombosis may be worthwhile.
*II
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3.2 INTRODUCTION
3.2.1 Incidence of Venous Thrombosis associated with Pregnancy
3.2.1.1 Venous Thromboembolism (VTE) remains the leading cause of maternal 
mortality in the United Kingdom (8). The recent Report on Confidential Enquiries into 
Maternal Deaths in the UK in the triennium 1994-1996 documented a total of 46 deaths 
from pulmonaiy embolism, 15 of which occun ed antepartum, 25 postpartum 
(excluding late postpartum deaths), 3 after abortion / ectopic pregnancy and 3 for which 
details were unavailable (8). The number of maternal deaths attributable to VTE had 
increased compared ivith the previous confidential enquiries report for the preceding 
triennium. The documented incidence of VTE associated with pregnancy appears to 
vary considerably. It is only within the past 10-15 years that objective tests have been 
performed routinely in obstetric patients with suspected VTE. Many of the published 
figures which document the incidence of VTE in pregnancy include events which were 
diagnosed clinically, which is now considered unreliable (173,174). There are few data 
reporting the incidence of objectively confinned VTE associated with pregnancy.
James et al, in a study of 30 000 pregnancies, estimated the incidence of thrombotic 
complications related to pregnancy at 1 per 1000, although this figure also included 
superficial thrombophlebitis and pelvic vein thrombosis (175). Kierkegaard et al 
studied over 14 000 pregnancies and estimated the incidence of objectively proven 
DVT at 0.74 per 1000 (174). These figures are consistent with a 10-year review of 
Scottish maternity’s which were complicated by VTE (176).
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3.2.2 Risk Factors for Pregnancy Associated VTE
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3.2.2.1 Pregnancy is accompanied by significant physiological changes in haemostasis 
(table 3.1). Elevations of coagulation factors Vc, VIIIc, Xc, von Willebrand factor |
antigen, and decreases in both total and free protein S are reported (reviewed in (177)). i
A recent prospective cross-sectional study of 239 women throughout pregnancy
observed that up to 38% of pregnant subjects develop activated protein C (ARC) 
resistance by the third trimester, which occurs in the absence of the factor V FVL 
(FVL) gene mutation (43). This acquired ARC resistance appears to correlate with 
increased concentrations of coagulation factors Vc and VIIIc and a decrease in protein 
S concentration. Coagulation activation markers are also elevated, particularly in the 
third trimester (43). There are no significant changes in the plasma levels of protein C 
or antithrombin throughout pregnancy (43,177). Fibrinolytic activity is impaired during 
pregnancy, relating in part to elevations in placentally-derived plasminogen activator 
inhibitor type 2 (RAI-2) which is produced in substantial quantities during pregnancy 
(177). These physiological changes produce a relative tlirombotic tendency during 
pregnancy.
.3.2.2.2 The physiological changes in the coagulation and fibrinolytic systems in 
pregnancy are accompanied by increased venous capacity and distensibility, leading to 
a reduction in velocity of blood flow within the lower limbs (178). The reduction in 
blood flow appears more marked in the left leg (178). In addition, it has been noted that 
women delivered by caesarean section appear to have reduced blood flow in the 
proximal leg veins compared to those delivered vaginally (179). These effects may be 
compounded by varying degrees of venous obstruction to both the left iliac vein and the 
inferior vena cava by the gravid uterus. Other risk factors for VTE may be apparent at
I
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#time of booking or develop during pregnancy. These include caesarean section, 
previous VTE, age over 35 years, obesity (>80 kg), high parity (4 or more), infection, 
pre-eclampsia, immobility, varicose veins, thrombophilia, or major current illness 
(8,176,180) (see table 3.2). The paper by Macklon et al (176) describes an approximate 
two-fold increase in incidence of both antenatal and puerperal DVT in women aged >
35 years, and almost a three-fold increased incidence of PE. This paper also 
documented a more than two-fold increased incidence of puerperal VTE if delivery was 
by caesarean section compared with vaginal delivery; the incidence was even higher if 
delivery was by emergency section.
3.2.3 Inherited Thrombophilia as a risk factor for VTE associated with Pregnancy
Observational Studies in Thrombophilic cohorts
3.2.3.1 Until recently, there were few published data on the contribution of inherited 
thrombophilic abnormalities to the development of VTE associated with pregnancy.
Several papers have documented episodes of VTE during pregnancy or in the 
postpartum period in cohorts of individuals with known natural anticoagulant 
deficiencies. Conard et al studied subjects with deficiencies of antithrombin, protein C
Ior protein S from symptomatic families, during pregnancy and the postpartum period
for episodes of VTE (181). The incidence of VTE was increased in all three categories.
Those with antithrombin deficiency (n^25) had a very high risk of VTE (18%
developed VTE antepartum, 33% postpartum). Protein C deficient subjects (n=36)
developed events less frequently (7% antepartum, 19% postpartum), and those with
protein S deficiency (n=17) also had fewer thrombotic events (0% antepartum, 17%
postpartum). Friederich studied 60 previously asymptomatic women with deficiencies
.of the natural anticoagulants antithrombin (n==13), protein C (n=19) or protein S (n=28),
51
■p;.
through 169 pregnancies (182). These women were identified because of a family
history of VTE. The incidence of thrombotic events in the anticoagulant factor deficient
■
group was compared to that observed in women from the same families who had
normal levels of antithrombin, protein C and protein S (n=69, number of pregnancies in
this group =198). 4.1% of women with natural anticoagulant deficiencies developed
VTE (all in the third trimester or postpartum) compared with 0.5% in the non-deficient
group (odds ratio for VTE in the deficient group = 8). Pabinger studied 230 individuals
with natural anticoagulant deficiencies, again from symptomatic families, and noted
that 40% of those with antithrombin deficiency developed VTE related to pregnancy
(183). Hough retrospectively studied 80 women with thrombophilia during 215 
.pregnancies and reported VTE in 32% of those with antithrombin deficiency, 22% in
those with protein C deficiency, 14% in those with FVL and 12.5% in those with 
.protein S deficiency (184). All of these studies are retrospective and appear to suffer 
from selection bias, since the patients described are identified from symptomatic 
families, and in some cases combined thrombophilic abnormalities were present.
'Studies documentins prevalence of thrombophilia in obstetric patients with VTE
3.2.3.2 Recent studies have attempted to identify the prevalence of thrombopliilic 
abnormalities in women with pregnancy associated VTE.
,
3.2.3.3 De Boer et al investigated 30 highly selected women referred to a thrombosis 
unit with an episode of VTE related to pregnancy for thrombophilia (185). One patient 
was identified with antithrombin deficiency, 2 with deficiency of protein C and 1 with 
evidence of a lupus anticoagulant. In addition, 2 patients were reported with fibrinolytic 
abnormalities, which are not firmly established as risk factors for VTE. Unfortunately,
52
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this paper pre-dated the description of both FVL and the prothiombin 202 lOA 
mutations.
3.2.3.4 Hellgren et al investigated 34 women who had suffered an episode of VTE 
associated with pregnancy and found 20 (59%) with ARC resistance (186) (table 3.3).
Details of how these women were identified were not given. In addition, not all events 
were objectively diagnosed, subjects with other thrombophilias were excluded, and 
PCR was not performed on those with ARC resistance to confinn the presence of the 
FVL mutation. Since it is now appreciated that ARC resistance can occur in those 
without the FVL mutation, it is important to confirm FV genetic status with RCR.
3.2.3.5 Two other small studies have reported on the prevalence of FVL in obstetric 
patients with VTE. Hallak et al documented results of thrombophilia investigations 
performed on patients admitted to a high risk pregnancy unit over a two year period 
(187). This included patients with DVT, RE, transient ischaemic attack and 
cerebrovascular accidents. 15 patients were described, of whom 7 (4 RE, 2 DVT and 1 
sagittal sinus thrombosis) had FVL. This was a small study on a highly select group and 
therefore only limited conclusions can be drawn. Dizon-Townson et al screened 407
unselected obstetric patients for the FVL mutation (188). 14 (3%) were found to
'possess the mutation. 4/14 developed DVT, all in either the late second / third trimester 
or postpartum. The number of pregnancies studied here was very small; in addition, the
incidence of VTE related to pregnancy (if taken as representative) appears very high (1 
in 100, ten times that reported elsewhere). Of the 4 with FVL who developed DVT, 2 
had complicated pregnancies (one was a twin pregnancy with pre-eclampsia, the other 
was complicated by uterine atony and disseminated intravascular coagulation).
3.2.3.8 Thus far there are no data to determine if the prothrombin mutation is associated 
with a significant number of venous tlirombotic events related to pregnancy. This
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3.2.3.6 Hirsch et al reported that 6 (17%) of 35 women with pregnancy associated VTE 
possessed the FVL mutation (189). In 5/6 patients with FVL the episode of VTE 
occurred in the first trimester. 3 patients in the FVL group developed pulmonary 
embolism. One patient had coinheritance of both FVL and antithrombin deficiency; 
prothrombotic abnormalities were identified in a further 4 patients (protein C 
deficiency in 1, protein S deficiency in 1 and antiphospholipid syndrome in 2). It was 
noted that additional risks for VTE were present in 40% of the FVL group.
3.2.3.7 Bokarewa investigated 74 women with VTE, placental thrombosis and stroke 
related to pregnancy and found the FVL mutation in 46% (190). Unfortunately, this 
study did not describe what, if any, thrombophilic abnormalities were found in the 
remainder. It was noted that those with FVL had a predilection to develop VTE in the 
first trimester or postpartum. Women in this study were not investigated for the 
presence of the prothrombin 20210 G->A mutation, or for the C677T mutation in the '.m
MTHFR gene.
f
mutation is relatively common in the general population (2.2% in the West of Scotland)
(74), although the increased risk of VTE appears somewhat less than that posed by 
FVL (86-91). One case report has highlighted the prothrombin mutation as a possible 
risk factor for VTE associated with pregnancy (191), although there are no large studies 
to support this. Since both the FVL and prothrombin mutations are relatively common. -.fi
it could be argued that widespread screening for these mutations in early pregnancy
might be worthwhile in order to identify women at increased risk of VTE. However, 
screening is expensive, and the results may provoke important therapeutic issues. 
Indeed, unnecessary anticoagulation during pregnancy or the puerperium could itself
future uncertainty regarding appropriate methods of contraception. Clinicians may not 
prescribe the combined oral contraceptive in such a situation. Unplanned pregnancies
3.2.3.9 To examine tins important area further, we performed a study to determine
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produce considerable morbidity and mortality (192-194). Also, widespread random
■
screening may identify many asymptomatic females with these mutations, and cause
■I
could ensue with, in the presence of thrombophilia, an increased risk of VTE.
i
.1
1. The incidence of objectively confirmed VTE associated with pregnancy
2. The prevalence of thrombophilic defects amongst individuals with pregnancy 
associated VTE
3. The role of acquired risk factors (such as caesarean section, preeclampsia etc.) for 
VTE associated with pregnancy.
"I
3.3 PATIENTS. MATERIALS AND METHODS
3.3.1 Ethical approval was obtained from the local research ethics committee for this 
study. All participants gave written informed consent (see appendices 2 and 3). The 
study was based upon individuals who had attended for antenatal care and delivery at 
two Glasgow maternity units (Glasgow Royal Maternity Hospital; Southern General
Haemostasis in 1997 (195). The data presented here are those obtained for the duration
i
Hospital) and who had suffered an objectively confirmed episode of deep vein 
thrombosis (DVT) and / or pulmonaiy embolism (PE) during pregnancy or up to six
weeks post-partum. The study was commenced in 1995 (retrospectively) and continued
■
prospectively until December 1998. Patient data was obtained from the Infonnation and 
Statistics Division of the Common Services Agency for the National Health Service in 
Scotland (SMR2 data). A list of individuals who had been given an ICD code 
corresponding to either DVT or PE at the two maternity units between January 1985 -
December 1998 (14-year period) was obtained. The results from those women
■identified between January 1985 - December 1995 were published in Thrombosis and
%
S
of the entire study.
vi3.3.2 The following diagnostic codes (ICD9) were used to identify retrospective cases: 
DVT, 6713 and 6714 and PE 6732. Information was also obtained on females up to the 
age of 49 years who had been admitted to the acute medical receiving units of Glasgow 
Royal Infirmary or the Southern General Hospital and given heparin therapy, in an 
attempt to document cases of post-partum VTE who were not admitted to the maternity 
units. The case records of all individuals were scrutinised to verify that an objectively 
confirmed diagnosis of either DVT or PE had been obtained. Those with DVT were
included for study purposes if compression or Doppler ultrasound, or contrast
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venography, were diagnostic. Women with PE were included if ventilation-peifusion 
scanning was considered of either high or intennediate probability, and they had 
received at least a six-month course of anticoagulant therapy.
3.3.3 Individuals were invited by letter to attend a clinic for the purposes of interview 
and blood sampling. Infonnation was obtained on clinical risk factors for thrombosis 
(outlined by the Royal College of Obstetricians of the UK) during the affected 
pregnancy (180) (see table 3.2).
Blood Sampling
3.3.4 None of the individuals were pregnant at the time of blood sampling. Blood was 
obtained by fresh venepuncture, and added to 0.109 mol/L trisodium citrate (9 parts 
blood; 1 part anticoagulant). Samples were mixed gently and centrifuged at 2000g for 
10 minutes to obtain platelet poor plasma (PPP). The PPP was then centrifuged for a 
further 10 minutes at 2000g and the plasma separated into 1ml aliquots within four 
hours. Plasma samples were then stored in 1ml aliquots at -70^ C until analysis. 
Peripheral blood leucocytes were stored and used for DNA analysis.
Sample analysis
3.3.5 Samples were subject to a thrombophilia screen which included prothrombin 
time, activated partial thromboplastin time, thrombin time, antithrombin (AT) and 
protein C (PC) activity, free and total protein S antigens, lupus inhibitor screen (APTT 
performed on a mix of four parts patient platelet poor plasma to one part normal 
platelet poor plasma, and dilute Russells’ viper venom test with platelet neutralisation 
step), IgG and IgM anticardiolipin antibody assays and activated protein C-sensitivity
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j'iratio (APC-SR). PCR was performed to detect the FVL, prothrombin 20210 G~>A and | |
MTHFR C677T mutations.
3.3.6 AT activity was detennined by an automated, amidolytic antithrombin based 
assay (ATIII kit, Boehringer Mannheim; the standard used for this assay was 
commercial reference plasma Sigma calibrated against WHO International reference 
preparation for antithrombin III, human code 87/718). Protein C activity was measured 
by an automated, amidolytic assay using Protac™ C (American Diagnostica Inc) in the 
activation step and S-2366 (Kabi, Sweden) as the specific chiomogenic substrate (the 
standard used here was the WHO international standard for human plasma protein C, 
code 86/622). Protein S total and free antigens were measured by an established ELISA 
method (Dako Ltd, High Wycombe, Bucks). Anticardiolipin antibodies were also 
measured by an ELISA method (Cambridge Life Sciences kit).
»■
3.3.7 To test for the presence of a lupus anticoagulant, an APTT was performed on 
patient PPP, on pooled normal plasma, and on a mixture of four parts patient PPP to 
one part nonnal PPP. As a more specific test for a lupus anticoagulant, we also
;performed a Dilute Russell's viper venom time (DRVVT) on double spun plasma. This 
was performed as follows; 0.1ml dilute phospholipid was incubated with 0.1ml normal 
control plasma at 37  ^C for 30 seconds. 0,1ml of RVV reagent was added. This was 
incubated at 37  ^C for 30 seconds 0.1ml CaCb added. The time for clot fonnation was
;
recorded and the test was repeated on patient plasma. If the result with patient plasma 1
was longer than that with normal control plasma, these steps were repeated for normal
and patient plasmas, substituting washed freeze-thawed platelets for the dilute 
phospholipid reagent. The ratio of patient clotting times to normal clotting times was
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calculated for both DRVVT and platelet neutralisation procedure (PNP); The nonnal 
ratio is 0.9-1.09. Ratios of > 1.1 were retested with the PNP. 10% or greater shortening
normal donors of both male and female sex. Resistance to activated protein C was 
diagnosed when the APC-SR was below 2.6.
Identification o f the FVL mutation
3.3.9 DNA was isolated from peripheral blood leucocytes by an established technique 
(Nucleon, Coatbridge, Lanarkshire). This process involved six steps. Briefly, in the cell 
preparation stage, reagent A was added to citrated whole blood and centrifuged at 
1300g for 5 minutes. Cell lysis was achieved by addition of reagent B to the pellet. 
Deproteinisation occurs via addition of sodium perchlorate solution. DNA extraction 
with chloroform and Nucleon® resin was followed by DNA precipitation with cold 
absolute ethanol, and finally DNA washing. Following the manufacturers instmctions, 
this process took approximately 30-40 minutes.
3.3.10 The G1691A mutation in exon 10 of the factor V gene (nucleotides 1487-1701)
59
1
of the DRVVT with the PNP was considered a positive lupus test.
Test for Resistance to Activated Protein C
3.3.8 APC resistance was assessed by measuring the anticoagulant response in plasma
#on the addition of APC (Coatest, Chromogenix, Sweden). APC acts as an anticoagulant 
by degrading factors Va and Villa. Thus addition of APC to a plasma sample causes
prolongation of the APTT. The APC-sensitivity ratio (APC-SR) represents the ratio of
'
two APTT values, determined in the absence and presence of activated protein C.
,Normal range for our laboratory at the time of study was 2.6 - 4.5, derived from 76
, 1
enzyme digestion. The PCR conditions were as described for identification of the FVL
60
.■i
i
:S
was detected by loss of a cleavage site for Mnll. A  223 base-pair fragment was 
amplified from genomic DNA using the 5' primer (5'-
ACCCACAGAAAATGATGCCCAG-3', nucleotides 1566-1587) and the 3' primer 
(5TGCCCCATTATTTAGCCAGGAG3', nucleotides -66 to -10 of intron 10). The 
PCR conditions were as follows: 75-150ng of DNA in 15pg of TRIS-EDTA buffer 
under 50|l i 1 of mineral oil was heated in a theimal cycler to 96  ^C for 60 seconds and 
95  ^C for 180 seconds, and then held at 80  ^C for 10 minutes while 35pi of 
amplification solution was added. The amplification solution contained 5 pi of 20mM 
deoxynucleoside triphosphates, 200ng of each primer, 0.1 pi of 1.0 M magnesium 
chloride and 0.5U of Taq polymerase . Thirty cycles of 93  ^C for 60 seconds, 50  ^C for 
30 seconds, and 72  ^C for 90 seconds were followed by a final 10 minutes at 72  ^C.
Aliquots (lOpl) were digested for 12 houis at 37 C vrith lU M nll (New England
-
Biolabs) after the addition of 2.5pi of digest buffer. The fragments (measuring 37, 82 
and 104 bp for the 1691G allele and 82 and 141 bp for the mutant allele) were 
separated on 2% agarose gel and visualised with ethidium bromide.
Identification o f the Prothrombin 20210 G-M mutation
I3.3.11 The prothrombin gene was amplified using primers A (5 ’ - 
TTACAAGCCTGATGAAGGGA-3’) and B (5’-
CCATGAATAGCACTGGGAGCATTGAAGC-3’). The latter is designed with a 
C~>A substitution at position 20214 to create a restriction site for Hind 111 when the 
G->A transition is present. The normal allele lacks a Hind III restriction site and 
generates only a 345 bp fragment. A new Hind III site introduced into the amplified 
fragment from the mutant allele yields 2 fragments of 322 bp and 23 bp after restriction
I
mutation, and the fragments were separated on 2% agarose gel and visualised with 
ethidium bromide. i
Analysis o f the C677T mutation in the MTHFR stene
.3.3.12 A fragment of the MTHFR gene was amplified by PCR using the primers (5’-
I
TGAAGGAGAAGGTGTCTGCGGGA-3') and (5’AGGACGGTGCGGTGAGAGTG- 
3’). The PCR conditions were as described for detection of the FVL mutation. A 
fragment of 198 bp was obtained. lOpl of PCR product were digested using the Hinfl 
restriction endonuclease. Electrophoresis was perfonned on 2% agarose gel. Normal 
homozygotes were identified by the presence of a 198 bp fragment, C677T 
homozygotes identified by a 175 bp fragment, and heterozygotes by the presence of 
both fragments.
Statistical techniques
3.3.13 This study was retrospective, not prospective, with VTE as an endpoint already 
identified. We calculated odds ratios (OR) with 95% confidence intentais as estimates 
of the relative risk of thrombosis. Odds ratios were calculated as follows. Data 
(nominally labelled a,b,c,d) were constructed in standard 2x2 tables (data for those with 
risk factors in the first row, data for cases in the first column) (196). The OR was 
calculated as the cross-product ratio (ad/bc) (196). 95% confidence intervals were 
calculated according to Woolfs method i.e. the standard error of the natural logarithm 
of the OR (In OR) was calculated from (Vl/a + 1/b + 1/c + 1/d} and the 95% 
confidence intervals derived from In OR +/-1.96 (standard eiror}. An OR was 
considered to be statistically significant when the lower limit of the 95% Cl was >1.0 
(196).
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not had this confirmed by a radiological investigation. Since this small number were
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3.4 RESULTS
3.4.1 Maternity’s at each unit
3.4.1.1 Maternity unit 1 (GRMH) had a total of 61 383 maternity’s for the study period 
whilst unit 2 (SGH) had a total of 32 110. The study therefore encompassed a total
■93 493 maternity’s.
'S
3.4.2 Thrombotic events over the 14 year period (tables 3.4.3.5 and 3.61
3.4.2.1 During the study period 87 women had an episode of objectively confirmed
VTE related to pregnancy. In 78 women this was the first thrombotic event and in 9 this
was a recurrent thrombosis (8 previous DVT, 1 previous episode of superficial vein
thrombosis). None of the 9 individuals with a recurrent thrombosis had pregnancy as a
previous precipitating event. Table 3.4 provides details of diagnosis and gestation at
diagnosis in these 87 women. Table 3.5 shows the calculated incidence of tlirombosis 
.per 1000 maternity’s based upon a total of 93 493 maternity’s during the study period.
Table 3.6 shows thrombotic events per 10 000 women years at risk. First trimester was 
defined as up to and including 12 weeks gestation, second trimester 13-28 weeks, third 
trimester 29-term, puerperium up to 6 weeks following delivery. There were 64 cases 
of DVT, of which 44 (69%) occun ed in the antenatal period and 20 (31%) in the 
puerperium. Of 44 antenatal cases of DVT, 12 occurred in the first trimester, 8 in the 
second trimester and 24 in the third trimester. There were 23 cases of pulmonary 
embolism, 9 (39%) of which occurred in the antenatal period and 14 (61%) in the 
puerperium. Of 64 patients vrith DVT, 48 (75%) were left sided and 15 (23.4%) 
occurred on the right. One case was bilateral. We also identified 6 individuals who had 
been given a clinical diagnosis of DVT and received anticoagulant therapy but who had
diagnosed subjectively, we excluded them for the purposes our study.
3.4.4 Clinical risk factors for thrombosis (table 3.7)
3.4.3 Patients attending for interview and blood sampling
3.4.3.1 Of the total of 87 individuals with objectively proven venous thrombotic events, 
75 attended for interview and blood sampling (follow-up rate of 86%). Of this number, 
55 had DVT and 20 had PE. From this cohort we were able to obtain clinical 
information on risk factors for thrombotic events. All were subject to thrombophilia 
screening as described above. However, since the prothrombin 202100**^ A mutation 
was described in November 1996 (after the study was commenced), screening for this 
mutation (and for the MTHFR mutation) was introduced in our centre in 1997. We 
attempted to recall all women who had already participated in the study to screen for 
the prothrombin and MTHFR mutations. Not all reattended. In total, 55/75 women had 
PCR perfonned to determine the presence or absence of the prothrombin mutation. 
52/75 were screened for the C677T mutation in the MTHFR gene. 9 women had a 
history of VTE prior to the episode of pregnancy associated VTE (8 with previous DVT 
and 1 with a previous episode of SVT). 14 individuals were on oral anticoagulants at 
the time of blood sampling, limiting thrombophilia screening.
S
3.4.4.1 Table 3.7 demonstrates the prevalence of clinical risk factors for thrombosis 
detected in women with DVT and PE. It can be seen that clinical risks were common in 
both the DVT and PE groups. In total, 45/75 (60%) women had additional identifiable 
clinical risk factors for the development of VTE. 22/55 women with DVT and 8/20 
with PE had no evident clinical risk factors (other than pregnancy) for VTE (40% of
total cohort). Of these thirty individuals without clinical risk factors, six were
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subsequently found to possess thrombophilic defects (two with type I antithrombin 
deficiency, one with type II antitlirombin deficiency, one with protein C deficiency, one 
with heterozygous FVL, and one with heterozygous prothrombin 20210G-*»A 
mutation). Hence 32% (24/75) of episodes of VTE were not associated with either a 
clinical risk factor for thrombosis (other than pregnancy) or a tlirombophilic defect 
(although 20/75 were not screened for the prothrombin 202 lOA mutation). 7/20 (35%) 
cases in the patient group with PE were associated with caesarean section (all were 
emergency section) prior to the development of thrombosis, compared with 6/55 (11%) 
(4 emergency section, two elective) cases with DVT associated with caesarean section. 
The odds ratio for development of PE as compared with DVT associated with 
caesarean section was 4.4 (95% confidence interval 1.26-15.4).
3.4.5 Identifiable thrombophilic defects (table 3.81
3.4.5.1 Seventy-five women who attended for follow-up were screened for
■
thrombophilic defects. 7/75 (9.3%) were identified with antithrombin deficiency, 7/75 
(9.3%) with the FVL mutation, one with protein C deficiency and one with the
antiphospholipid syndrome (consistently elevated IgG anticardiolipin antibody levels 
and intermittently positive testing in the DRW T). No women were found to have 
deficiency of protein S. In addition, of 55 women who were screened for the 1
prothrombin 202lOA mutation, 5/55 (9.1%) were found to be heterozygous. One 
.patient was found to possess both the FVL and prothrombin mutations, both in 
heterozygous form. The total prevalence of established thrombophilia found in the
cohort of 75 was 26.7% (20/75). Of 52 women who were screened for the C677T 
mutation in the MTHFR gene, 3 (6%) were found to be homozygous for the C-^T 
transition, 24 (46%) heterozygous and 25 (48%) homozygous for the normal allele.
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Table 3.8 provides detailed information on those with heritable thrombophilia 
identified in the cohort, including family studies where performed. Of those with AT
Patients 16-19 were found to possess the protlirombin 20210A mutation (all
I s
.OÏ
deficiency, 4 had a type I deficiency phenotype (patients 1-4, table 3.8) and 3 had type
II deficiency phenotypes (patients 5-7). Individuals 8-14 were found to have the FVL 
mutation. In 6 women FVL was identified in the heterozygous state. One woman was
■homozygous for FVL. Individual 15 had a type I protein C deficiency phenotype.
heterozygous). Of note, 3/7 of those with AT deficiency (all type I antithrombin 
deficiencies) developed thrombotic events in the first trimester. Four individuals (2 
with AT deficiency, one with FVL and one with combined FVL and the prothiombin 
202 lOA mutation) had suffered previous thrombotic events (all DVT). Four of the 19
women who were found to have heritable thrombophilia had a positive family history
of VTE. Of 7 women who were found to possess the FVL mutation, six had at least 2
clinical risk factors for VTE. Only one woman with FVL did not have any other clinical
risk factors for VTE other than pregnancy. None of the women with FVL had
symptoms of PE. Of 5 women who were found to possess the prothrombin 202 lOA
mutation, 3 presented with PE. Four of 5 who were identified with the prothrombin :
.mutation also had two or more additional clinical risk factors for VTE.
Î
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3.5 DISCUSSION
3.5.1 This large study, covering over 93 000 maternity’s, estimates the overall 
incidence of objectively proven VTE related to pregnancy at 0.93 per 1000 maternity’s 
(95% confidence interval 0.73-1.13). The incidence of objectively proven DVT was 
0.68 per 1000 maternity’s (95% confidence interval 0.51-0.85) with 0.47/1000 
antenatal and 0.21/1000 puerperal (table 3.5). The incidence of objectively proven PE 
was 0.25 per 1000 maternity’s (95% confidence interval 0.15-0.35), 0.1/1000 antenatal 
and 0.15/1000 puerperal. These figures are similar to other published data (174- 
176,197). However, the true incidence of VTE associated with pregnancy may be a 
little higher, since our figures exclude those treated for DVT who did not have an 
objective test perfonned.
3.5.2 It is of interest that the majority (69%) of cases of DVT occurred in the antenatal
period, which has been noted in other studies (176,186,198). However, others have
found the incidence of puerperal tlnombosis to be higher (174,199). It has been
suggested that the relative increase in antenatal VTE and comparative decline in
incidence of puerperal VTE may reflect changing obstetric practice (200). For example,
in the past it was common for physicians to discourage maternal mobilisation in the
first week of the puerperium, or to prescribe puerperal oestrogen to suppress lactation.
It should be appreciated, however, that the puerperium remains the period of greatest
thrombotic risk, since the event rate during this six weeks is significantly greater than
■
the event rate antenatally (table 3.6). Considering the data in tenns of women years at 
risk, the puerperal DVT compared with antenatal DVT event rate appears almost three 
times greater (18.5 events per 10 000-woman years versus 6.4/10 000 years antenatal). 
The puerperal PE compared with antenatal PE event rate is increased ten-fold (13.0/10
000 years versus 1.3/10 000 years). The implication from these data is that, whilst 
antepartum thrombosis may now be more common in absolute terms, potentially a 
relatively greater number of episodes of VTE may be prevented per week of 
anticoagulant therapy used in the puerperium than in the antenatal period.
3.5.3 We found that the majority of cases of DVT in relation to pregnancy occurred in 
the venous system of the left leg (75%), which has been previously noted in one other 
study (201). This finding may relate to the recently noted reduction in venous flow 
within the left femoral vein during pregnancy, which may be due to differences in 
venous anatomy (178). It has also been noted that venous flow within the leg veins 
appears more sluggish following operative compared with vaginal delivery (179).
3.5.4 A significant number (60%) of women with VTE related to pregnancy had 
additional clinical risk factors for thrombosis. It was of interest that caesarean section 
(CS) (particularly emergency CS) was significantly associated with development of PE; 
35% of all women who presented with PE had emergency CS as an additional risk for 
VTE, compared with 11% of those with DVT. Indeed, 50% of all puerperal PE were 
associated with emergency CS. The odds ratio for development of PE as compared with 
DVT associated with CS was 4.4 (95% confidence interval 1.26-15.4). The reason for
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this observation is unclear; we may speculate that CS is a major risk factor for proximal 
VTE, which is much more likely to lead to PE than more distal events.
3.5.5 Our study is the largest yet reported which has examined the role of 
thrombophilia as a risk for pregnancy associated VTE. Unlike most other reports, our 
study considers consecutive women presenting vrith an episode of VTE related to
pregnancy, and therefore selection bias is less likely. Although we were unable to
obtain blood samples from all individuals who developed VTE during the study period, 
we examined a large cohort and had a high follow-up rate - 75/87 (86%) with VTE
were tested for thrombophilic defects. We found a lower prevalence of the FVL 
mutation in women with VTE related to pregnancy (9.3%) compared with other
researchers (186,189,190). In particular, the studies of Bokarewa and Hellgren report 
that 46-60% of women who suffered pregnancy associated VTE possessed the FVL 
mutation (186,190). Both of these studies originate from Sweden, where FVL appears 
significantly more prevalent compared with the UK (202), which may help to explain 
this observation. Selection bias may also explain the higher prevalence of FVL carriers 
seen in these studies, since little information is provided in either study of precisely 
how patients were identified. Neither of these studies documented any associated 
clinical risk factors for VTE during pregnancy. We found that additional clinical risk 
factors were common in those with FVL who developed VTE - of seven women with
i
FVL who developed VTE, six had at least two additional clinical risks. It seems likely 
that in most cases additional clinical risks (or an additional thrombophilia) may be
.
necessary for the development of VTE during pregnancy in carriers of FVL. It is also
noteworthy that all seven women with FVL presented with DVT, and none had 
symptoms of PE. Data indicate a significantly lower prevalence of the FVL mutation in
those presenting with isolated PE compared with DVT or DVT and PE (203-206). That
■
is, the relative risk of PE in carriers of FVL appears lower than for DVT (206). The
' ■reason for this observation is unclear, although it is hypothesised that higher thrombin
provide details of prevalence of FVL in those with DVT compared with PE (186,190).
levels seen in those with FVL may lead to the production of a more stable thrombus ;
which is less likely to embolise (206). The studies of Bokarewa and Hellgren do not
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the prothrombin mutation.
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The smaller study by Hirsch describes pregnancy associated PE in 6/10 women with 
FVL (189). However, this paper may also suffer selection bias since patient recruitment 
criteria are not included.
3.5.6 We found deficiency of antithrombin was as common in our cohort as the FVL 
mutation. All women who were identified with type I antithrombin deficiency 
developed VTE in either the first or second trimester, in keeping with the findings of 
others (183). Three women with type II antithrombin deficiency developed VTE in the 
puerperium. Only one patient had protein C deficiency and none had deficiency of 
protein S. One woman was found to have persistently elevated IgG anticardiolipin ..i
antibody levels (varying between 30-40 units) and intermittently positive lupus
anticoagulant testing, although the presence of this during her pregnancy could not be 
confinned.
3.5.7 Of 75 women who were screened for deficiencies of natural anticoagulants, 
antiphospholipid syndrome and the FVL mutation, 55 were also screened for the 
recently described prothrombin 20210G->A mutation. Five women were found to be 
heterozygous for this mutation. One woman was doubly heterozygous for both the FVL 
and prothrombin mutations. As was the case for those with FVL, additional clinical risk 
factors were also common in this group. Three of five presented with pulmonary 
embolism. Currently there are no data on the relative risks of DVT and PE in carriers of
3.5.8 We compared the prevalence of the FVL and prothrombin mutations in women 
with VTE to that obtained in over 200 random unselected umbilical cord blood
Î
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controls. The cord controls were obtained from a Glasgow maternity unit; this data has 
previously been published (74). Our control data estimates the prevalence of FVL at 
2.2% and the prothrombin mutation at 2.2% (5/224 cord blood controls for both 
mutations). These figures are similar to those obtained by other researchers in the 
United Kingdom: Lowe recently documented the prevalence of FVL in Glasgow at 
2.5% in a large (almost 1300 subjects) random population study (61), and Brown has 
estimated the prevalence of the protlirombin mutation at 2.6% (13/508 healthy subjects) 
(87). The prevalence of the homozygous C677T mutation in cord controls was 12% 
(19/158 consecutive cord blood samples). This is in agreement with published 
prevalence figures (112). In addition, we compared the prevalence of types I and II 
antithrombin deficiency in our cohort to that obtained in over 9000 healthy blood 
donors in the West of Scotland (published in (40,41)). The risk of VTE related to 
pregnancy was significantly increased in carriers of both FVL (OR 4.5, 95% confidence 
interval 2.1-14.5) and prothrombin mutations (OR 4.4, 95% confidence interval 1.2-16) 
(table 3.9). The calculated risk was particularly high in those with type I (OR 282, 95% 
confidence interval 31-2532) and type II (OR 28, 95% confidence interval 5.5-142) 
antithrombin deficiency. These figures represent the first estimates of venous 
thrombotic risk for women during pregnancy with the FVL and prothrombin mutations. 
Indeed, this study is the first to comment upon the prevalence o f the prothrombin 
mutation in women with VTE associated with pregnancy. Whilst several other groups 
have commented upon the prevalence of the FVL mutation, they have not compared 
them to their general population prevalence. Since FVL shows a marked geographical 
variation (202), this is an important consideration. Other researchers have estimated the 
risk of VTE in women with antithrombin deficiency, and also found this to be high 
during pregnancy (181,183).
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3.5.9 Fifty-two women were screened for the C677T mutation in the MTHFR gene.
Homozygosity for this mutation is associated with elevated plasma homocysteine levels
in the presence of folate deficiency (108,110,207). Girelli recently demonstrated that
individuals homozygous for the C677T mutation with adequate folate stores do not
have elevated plasma homocysteine levels (110). Since pregnancy is associated with
increased folate demands, and supplementation is not generally continued beyond the 
,first trimester, this mutation might theoretically be relevant to pregnancy complications. 
However, we did not find a higher prevalence of homozygous C ^T  carriers in cases 
compared with controls (OR 0.45, 95% confidence interval 0.13-1.58). Kluijtmans
.recently concluded that this mutation is not a risk factor for VTE (208). However, this 
mutation may be important in the development of neural tube defects (112), severe 
preeclampsia and fetal growth retardation (155).
I
3.5.10 For the purposes of comparison, we should ideally have determined the 
prevalence of thrombophilia in pregnant women without a history of VTE. However, 
the study was retrospective (necessary because of the infrequency of maternal VTE), 
not prospective, and therefore this approach was impractical. In addition, there is no
■evidence that thrombophilia impairs the ability to conceive, although there is some 
evidence that women with thrombophilia are at increased risk of fetal loss (158,159).
We therefore feel that our comparisons are valid.
3.5.11 In summary, this study of thrombotic events occurring during pregnancy / 
puerperium has shown that antithrombin deficiency carries a very high risk of maternal 
VTE. The FVL and more recently described prothrombin mutations are more prevalent.
I
though less significant, risk factors for the development of pregnancy associated
'1
thromboembolism. Most women with the FVL or prothrombin mutations who develop 
VTE have additional clinical risk factors during pregnancy. Our findings do not lend 
support to the idea of unselected screening for either mutation during pregnancy, since 
relatively few thrombotic events would be prevented and the unnecessary use of 
anticoagulants in such individuals without other risk factors might increase morbidity 
and mortality. However, selective screening (for example, in those with a personal or 
strong family history of proven venous thrombosis) may be worthwhile, as suggested 
by some researchers (209). In order to reduce the incidence of pregnancy associated 
VTE, clinicians must be aware of clinical risks during pregnancy, and consider the use 
of anticoagulant therapy in those with multiple risk factors. Assessment for clinical
risks should commence at confirmation of pregnancy, and be the subject of continual
-review throughout pregnancy, deliveiy and the puerperium. In selected cases, for 
example women with a previous episode of VTE, preconceptual assessment for clinical 
risk factors (such as gross obesity, high parity) should be considered.
k:
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Table 3.1 Changes in Haemostatic Parameters during Pregnancy
ifA*'am@TaMiB*r*j!Msmv*aw*i»eaamAR*S^A!es':^aiHW:œ«TIncreased Decreased
Va Total PS
Villa Free PS
Xa
Von Willebrand factor
Resistance to AFC 
Activation markers
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Table 3.2 Factors that increase the Risk of Venous Thromboembolism in 
Pregnancy
Risk Factor
■«
■IÎ
■SAge >35 years 
Obesity (>80 kg)
Para 4 or more
.
Gross Varicose Veins 
Current infection 
Pre-eclampsia 
Immobility
Major cunent illness (including nephrotic 
syndrome and inflammatory bowel disease)
Caesarean section, particularly emergency section 
Personal or family history of VTE 
Known inherited or acquired thrombophilia 
Hyperemesis
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Table 3.3 Prevalence of factor V Leiden / APC resistance in Women with VTE 
related to Pregnancy.
Study Number ofCsffiBCTeBa«sgpn»Fca»ififfla>W4»if?tjr^ »=tsteaiÿ^ jS»i^ ani5}dteij>j^ j^ yWi5Pf»ga^ i«!*,ti.i;) ^ T-wwur^ wJWB'xt wriff.t lUL-v-^ iv t'T'i : Hi ; t) w* t Outcome Comments
participants
Hellgren (186) 34 women with VTE 59% APC resistant PCR not done
during pregnancy ?selection criteria
Hahak (187) 15 (not all VTE) 7FVL CVA, TIA included
Highly selected
Dizon-Townson 14 women with FVL 4 developed VTE 
(188)
Hirsch (189) 35 women with VTE 17% FVL ?selection criteria
related to pregnancy
Bokarewa (190) 74 (not all VTE) 46% FVL Yselection criteria
Placental thrombosis, 
CVA included
FVL-factor V Leiden 
CVA-cerebrovascular accident 
TIA-transient ischaemic attack
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Table 3.4 Trimester distribution of Thrombotic Events.
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DVT Pulmonary Embolism
Number 64 23
Total Antenatal Events 44 9
First trimester 12 0
Second trimester 8 1
Third trimester 24 8
Puerperium 20 14
i
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Table 3.5 Incidence of Maternal VTE based upon a Total of 93 493 Maternity’s 
during the Study Period.
Event rate (per 1000 maternity’s) DVT (95% Cl) Pulmonary Embolism (95%C1)
Total 0.68 (0.51-0.85) 0.25 (0.15-0.35)
Antenatal 0.47 (0.33-0.61) 0.1 (0.04-0.16)
Puerperal 0.21 (0.12-0.3) 0.15 (0.07-0.22)
s
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Table 3.6 Event Rates per 10 000 Women-Years at Risk.
Event rate (per 10 000 years at risk) DVT Pulmonaiy Embolism
Antenatal 6.4 1.3
Puerperal 18.5 13.0
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Table 3.7 Clinical Risk Factors (CRF) for Thrombosis detected in 75 Women 
attending for Follow-up. Also Shown are Numbers of Women Subsequently Found
DVT^
Number
55
Number
none 
22 (40%)
Of Clinical
one 
~ 14 (25%)
Risk factors
two 
11 (20%)
three or more 
8(15%)
PE 20 8 (40%) 4 (20%) 6 (30%) 2 (10%)
Total 75 30 (40%) 18 (24%) 17 (23%) 10 (13%)
With
detectable
thrombophilia
6 (20%) 4 (22.2%) 7 (41.2%) 3 (33.3%)
.
with Thrombophilia
i
Î
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Table 3,8 Details of Women Found to Have Heritable Thrombophilic Defects.
Patient Diagnosis Gestation Thrombophilia Family Study Clinical Risk 
Factors
1 DVT 1 AT 57/55  ^untested previous VTE
2 DVT 1 AT 48/45  ^mother, brother 
AT deficient
nil
3 DVT 1 AT 57/45  ^father, sister 
AT deficient
nil
4 DVT 2 AT 45/49  ^untested previous VTE
5 DVT PP AT 74/86  ^mother (symptomatic)
family history
6 PE PP AT 73/88  ^mother CVA aged 32 years
emergency CS 
twin pregnancy
7 DVT PP AT 56/72  ^untested nil8 DVT 1 FVL +/-  ^untested previous VTE 
parity
9 DVT PP FVL +/-  ^sister
(symptomatic)
weight
family history
10 DVT 3 FVL +/-  ^sister
(symptomatic)
colitis
family history
11 DVT 3 FVL +/-  ^sister age, parity
(symptomatic) 
 ^untested
family history
DVT 3 FVL +/- previous VTE 
weight
13 DVT 1 FVL +/-  ^untested nil
14 DVT 1 FVL +/+  ^untested hyperemesis
immobility
15 DVT 3 PC 55/62  ^untested nil
16 PE PP PT20210A  ^untested emergency CS 
preeclampsia
17 PE 3 PT20210A  ^untested nil
18 DVT 1 PT20210A  ^untested previous VTE
 ^untested
weight
19 PE PP PT20210A emergency CS
preeclampsia
weight
 ^patient also heterozygous for PT 202 lOA
Individuals 1-4 type I AT deficiency, 5-7 type II AT deficiency, 8-14 FVL, 15 PC 
deficiency.
AT, antithrombin: normal range 83-128 lU/dl. Figures given are activity/antigen. 
PC, protein C: normal range 74-128 U/dl. Figures given are activity/antigen.
FVL +/- heterozygous; +/+ homozygous
PT20210A heterozygous for prothrombin 20210 G-»A mutation
CVA, cerebrovascular accident
 ^ families with no history of thrombosis other than in propositus 
 ^ families with genetically affected relatives, symptomatic for venous thrombosis 
 ^genetically affected with arterial thrombotic event
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Thrombophilia Cases General
Population’^
Odds ratio 95% Cl
Prothrombin 202 lOA present
5 5 4.4 1.2-16
absent 50 219
FVL
present 7 5 4.5 2.1-14.5
absent 68 219
C677T
+/+^ ' 3 19 0.45 0.13-1.58
■t/™ and 7- 49 139
Antithrombin
Type 1® deficiency present 4 1 282 31-2532
absent 71 4999
Type 2® deficiency present 3 3 28 5.5-142
absent 72 1997
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Table 3.9 Prevalence of FVL, Prothrombin 20210A, C677T Mutations and 
Antithrombin Deficiency in Cases and in the General Population.
I
%
Prevalences of FVL and prothrombin 202 lOA mutations in the general population 
were obtained by genotyping 224 random unselected cord blood controls in our area 
[McColl et al (74)]. The prevalence of the three MTHFR genotypes were obtained by 
analysis of 158 cord controls [McColl et al (74)]. The prevalence of antithrombin 
deficiency in our area has been published by Tait et al (40).
qualitative antithrombin deficiency
® quantitative antithrombin deficiency
% homozygous for mutant allele
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CHAPTER 4
INCroENCE OF SUPERFICIAL VEIN THROMBOSIS 
(THROMBOPHLEBITIS) ASSOCIATED WITH PREGNANCY AND 
PREVALENCE OF THROMBOPHILIC ABNORMALITIES
4.1 SUMMARY
.4.4.1 We have determined the incidence of clinically diagnosed S VT associated with 
pregnancy and the early post-partum period in a retrospective study of 72 000 
maternity’s. 49 cases occurring in 47 individuals were recorded, with an overall 
incidence of 0.68/1000 maternity’s (95% Cl 0.48-0.88). The incidence in the early post- 
partum period (0.54/1000 maternity’s) was markedly higher than in the antenatal 
period. None had a previous history of deep vein thrombosis or pulmonary embolism. 
Twenty-four were screened for established thrombophilic abnormalities, with only one 
abnormality detected (heterozygous FVL). The risk of SVT was increased, though not 
significantly, in carriers of the FVL mutation (OR 1.83; 95% Cl 0.2-16.4). After a 
mean follow-up period of four years, none of the twenty-four had subsequently 
developed DVT or PE. Thrombophilia may play a minor role in the aetiology of SVT 
associated with pregnancy, although a larger study is required to confiiin this.
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4.2 INTRODUCTION
4.2.1 Pregnancy and the puerperium are recognised as periods of considerable risk for 
the development of deep venous tiirombosis (DVT) and pulmonary embolism (PE) (8). 
We have documented the incidence of objectively confirmed DVT and PE associated 
with pregnancy, and examined the role of both inherited and acquired risks for their 
development (195). There are few data regarding the incidence of superficial venous 
thrombotic (SVT, thrombophlebitis) events in association with pregnancy. SVT has 
been reported in association with deficiencies of both protein C and S and also in those 
with APC resistance (39,54). There are also few data to detennine if tlirombophilia 
plays a significant role in the aetiology of SVT. To investigate this further, we have 
performed a retrospective study of women who developed clinically diagnosed SVT 
without evidence of DVT or PE associated with pregnancy at two maternity units 
(Glasgow Royal Maternity Hospital and the Southern General NHS Trust) in Glasgow 
over the period January 1985 - December 1995. The aims of the study were to 
detennine the incidence of SVT associated with pregnancy, document associated 
clinical risk factors, and to perform thrombophilia screening to determine the 
prevalence of prothrombotic abnormalities in this group.
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4.3 PATIENTS. MATERIALS AND METHODS
4.3.1 The study was commenced in 1995 and completed in 1996. A list of women with 
ICD9 codes conesponding to superficial vein thrombosis (superficial thrombophlebitis) 
(ICD9-671.2) occurring during pregnancy or the early post-paitum period (up to the 
point of discharge after delivery) was obtained from the information and statistics 
division of the common sei-vices agency using SMR2 returns. The study was based 
upon women attending one of two maternity units in Glasgow between the years 1985- 
1995 inclusive. From the patient list, case records were examined to confirm that a 
clinical diagnosis of SVT had been recorded and also to obtain clinical data. For the 
purposes of oui’ study, SVT was present if the attending doctor felt that there was 
clinical evidence of superficial thrombus formation in one or both lower limbs with or 
without limb swelling or inflammation. Women were contacted and invited to attend 
for interview and blood sampling. All participants gave written informed consent. The 
study met with the approval of the local ethics committee. Women were screened for 
deficiency of antithrombin, protein C, protein S, for APC resistance / FVL, and for 
evidence of lupus anticoagulant / elevated IgG or IgM anticardiolipin antibodies. The 
study was completed in 1996, and hence women were not screened for the prothrombin 
20210G-^A mutation, which was described in November 1996.
4.3.2 For the purposes of comparison, the prevalence of thrombophilic abnormalities in 
cases was compared to that obtained in over 200 random unselected cord controls, as 
described in Chapter thi ee.
4.3.3 Clinical risk factors (CRF) for development of VTE
4.3.3.1 Data on possible clinical risk factors for VTE (table 1, chapter 3) was obtained
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from the patient case-notes, supplemented by information obtained at interview.
4.3.4 Blood Sampling
4.3.4.1 None of the individuals were pregnant at the time of blood sampling and none 
were on anticoagulants. Women were tested for thrombophilia at least six months after 
the event. Blood was obtained by fresh venepuncture, and added to 0.109 mol/L 
trisodium citrate (9 parts blood: 1 part anticoagulant). Samples were mixed gently and 
centrifuged at 2000g for 10 minutes to obtain platelet poor plasma (PPP). The PPP was 
then centrifuged for a further 10 minutes at 2000g and the plasma separated into 1ml 
aliquots within four hours. Plasma samples were then stored in 1ml aliquots at -70^ C 
until analysis. Peripheral blood leucocytes were stored and used for DNA analysis.
4.3.5 Sample analysis
4.3.5.1 Samples were subject to a thrombophilia screen which included prothrombin 
time, activated partial thromboplastin time, thrombin time, antithrombin and protein C 
activity, free and total protein S antigens, lupus anticoagulant screen (APTT performed 
on a mix of four parts patient platelet poor plasma to one part normal platelet poor 
plasma, and dilute Russells’ viper venom test with platelet neutralisation step), IgG and 
IgM anticardiolipin antibody assays and APC-SR. Testing for the FVL mutation was 
perfonned on all individuals in one of the units and in those with a low or borderline 
APC-SR (APC-SR less than 2.9) in the other unit. The methodology used for the 
coagulation assays, and PCR for the FVL mutation has been described in Chapter 3.
4.3.6 Statistical techniques
4.3.6.1 Ninety-five percent confidence intervals for the incidence of maternal SVT
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were determined by multiplying the standard error by 1.96. Since the study was 
retrospective with SVT as an endpoint already identified, we calculated odds ratios 
(OR) with 95% confidence intervals as estimates of the relative risk of thrombosis, as 
described in Chapter 3.
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4.4 RESULTS
I4.4,1 During the study period there were 72 200 maternity’s, with 49 cases of SVT 
identified which occurred in 47 women. All cases of puerperal SVT occurred within J;3
one week of delivery, with no patients in the cohort readmitted following discharge
from hospital with SVT. The median age at time of event was 30 years (range 20-44). Jl
None had a previous history of DVT or PE. Table 4.1 shows the calculated incidence of
■
SVT per 1000 maternity’s. The overall incidence of SVT was 0.68 per 1000 
maternity’s (95% confidence interval 0.48-0.88). Puerperal SVT (0.54 per 1000, 95% ■'i
confidence interval 0.37-0.71) predominated over antenatal SVT (0.14 per 1000, 95% Iconfidence interval 0.06-0.22). 5/47 individuals (3 antenatal, 2 puerperal) were
screened to exclude possible DVT using Doppler ultrasound (all were negative), with
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"Ithe remainder not tested objectively for underlying DVT. Clinical risk factors (CRF) Iidentified for the development of thrombosis included pre-existing varicose veins (13 
women), age > 35 years (8 women), weight > 80 kg (8 women), parity 4 or greater (6 
women) and caesarean section (2 women) (figure 4.1). Most patients were treated 
symptomatically with non-steroidal anti-inflammatory drugs. Three patients, all with 
puerperal SVT, received short-term subcutaneous heparin (maximum period 1 week).
In two cases heparin was administered following the event and in one case was being 
given as thromboprophylaxis following emergency caesarean section when SVT 
occurred.
4.4.2 Twenty-four of forty-seven (51%) attended for follow-up and blood sampling (the 
others had either moved away from the area or were unwilling to participate for blood 
sampling). Only one individual of the 24 screened was found to possess a 
thrombophilic abnormality (heterozygous FVL). No deficiencies of antithrombin.
exclude DVT was not performed in either subsequent case. Neither of these two 
individuals was found to possess a thrombophilic abnormality.
■
protein C or protein S, abnormal lupus / anticardiolipin tests were found. Mean interval 
from time of SVT to follow-up in these 24 women was 48 months (range 12-125), with
'1none having developed either DVT or PE during this period. However, 2 individuals 
each had a second episode of SVT during subsequent pregnancies. An objective test to
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4.5 DISCUSSION
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4.5.1 The incidence of SVT associated with pregnancy (0.68 per 1000 maternity’s, 95% 
confidence interval 0.48-0.88) appears comparable to that documented for DVT 
associated with pregnancy (0.68 per 1000, 95% confidence interval 0.51-0.85). The true 
incidence is likely to be higher since we may have missed some women who developed 
SVT following discharge from hospital. Such a situation might not result in hospital 
admission, since SVT is generally regarded as a benign condition compared with DVT 
or PE. Also, some women with leg pain and / or swelling who underwent radiological 
examination to exclude DVT may have had SVT, but this may not have been coded as 
such. Macklon et al documented the incidence of maternal SVT over the period 1983- 
1992 in Scotland at between 1.36-2.5 per 1000 maternity’s in women under 35 years 
(176). However, this study was based upon national SMR2 discharge data and did not 
involve an examination of case notes to confirm accuracy. We detected a considerable 
number of women who had been given a diagnostic code corresponding to SVT but in 
whom we could find no evidence of this in the case-notes. In many of these instances 
the patients either had vulval or leg varicosities without clinical evidence of 
thrombosis.
4.5.2 We noted a marked propensity for SVT to occur in the first week of the post­
partum period (39/49, 80%) which has been noted in one smaller study (175). This is in 
contrast to women who develop DVT related to pregnancy, in which a large proportion 
present during the antenatal period (69% of our cohort with DVT presented during the 
antenatal period, chapter 3) (175,176,195). This finding may be explained, at least in 
part, by selection bias, since women are more likely to be diagnosed with SVT whilst in 
hospital compared with those who have been discharged.
_;i|
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4.5.3 Over 27% of those affected had pre-existing varicose veins, suggesting that I
varicosities may be a significant risk factor for the development of SVT. Only 4% of
cases were associated with caesarean section. Although no cases of DVT were |
M
documented, relatively few women were investigated for underlying DVT (5/47).
Without performing objective testing for DVT, we cannot be certain that none had 
underlying DVT. In addition, we only have limited follow-up data (24/47, 51%) in 
which none of the women had subsequently developed DVT or PE (mean follow-up 
period 48 months). The association between SVT and DVT has recently been examined 
by Bounameaux et al in a study of 551 consecutive patients presenting with SVT (210).
This study found coexisting DVT in 5.6% of their cohort, all of whom were screened
objectively for DVT. Those found with DVT tended to be older with a history of
immobility. Of the remainder, a further 1.7% developed DVT at three months follow- 7 |
up. Chengelis et al reported that 11% of 263 patients with SVT developed progression
■ Ïof thrombosis from the superficial to the deep veins (211) and Blumenberg reported g
8.6% of 232 patients with SVT had coexisting DVT (212). Clearly, SVT may progress 
to DVT, particularly if SVT involves the proximal superficial saphenous vein (212),
'1and in such a situation imaging to exclude DVT is indicated.
4.5.4 In women whom we were able to follow-up, we found only one individual with 
the FVL mutation (4.2% of the cohort; 95% Cl 0-12.2), and none with deficiencies of 'IPC, PS, antithrombin or antiphospholipid syndrome. The number of women whom we 
were able to follow-up was rather low, perhaps because the condition is not regarded as
■ 'Ia serious health problem to those afflicted, and therefore the motivation to participate in %
3@such a study is less. Unfortunately our study was completed before the description of.
Y
the prothrombin 202 lOA mutation, and hence women were not tested for this 
thrombophilia. The prevalence of the FVL mutation in women with SVT was compared
Ito that obtained in cord blood controls. The odds ratio for development of SVT in Icarriers of FVL was increased, though the figure is not statistically significant (OR I1.83, 95% confidence interval 0.2-16.4). However, we appreciate that the numbers 
followed-up are relatively small (51% of the cohort). There are few data on the g
relationship of thrombophilia to SVT. Since our study, de Moerloose et al have 
investigated the prevalence of FVL and the prothrombin mutation in 112 consecutive 
patients with SVT of the lower limbs (213). These patients were not selected for 
development of SVT in relation to pregnancy. Those with FVL appeared to have an 
increased risk of SVT compared to controls (OR 2.51, 95% confidence interval 1.04-
independent risk factor for SVT.
the post-partum period. Additional clinical risk factors for VTE are common in those
6.24). However, clearly the increased risk of SVT observed in those vrith FVL in this f |
■7Study is much lower than the risk of DVT or PE quoted for carriers of the FVL
mutation (5-10 fold) (63). The OR was also increased for carriers of the prothrombin 
mutation (OR 3.28,95% confidence interval 0.46-36.8), although this was not istatistically significant. In this study, BMI > 28 kg/m^ was also noted to be an |
,
4.5.5 In conclusion, SVT associated with pregnancy appears particularly common in gï
affected. Tlu'ombophilia may play a relatively minor role in its aetiology, although a
■■jï
larger study is required to fully address this issue. This condition may occur as a result #Iof physical factors associated with pregnancy and delivery (increased venous pressure,
4-,T
venodilation, immobility during deliveiy) and of the physiological prothrombotic state 
conferred by pregnancy itself. From our limited data there appears no requirement for
::7li
extensive thrombophilia screening in those affected, except perhaps in those with 
recurrent events or those with a strong family history of venous thrombosis.
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Table 4.1 Incidence of Superficial Vein Thrombosis associated with Pregnancy,
Antepartum + Post-Partum 49 0.68 0.48-0.88
Number Incidence per 1000 maternity’s 95% Cl
$
Antepartum 10 0.14 0.06-0.22 SI:
Post-Partum 39 0.54 0.37-0.71 S
I
1
IJ
:
. -'493
i
Figure 4.1 Prevalence of Clinical Risk Factors in 47 Women with Superficial Vein 
Thrombosis Related to Pregnancy.
caesarean section
Parity >3
wei^Tt>80kg
Age >35 years
Varicose veins
0 2 10 12 14
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CHAPTER 5 
LIPOPROTEIN (a), CHOLESTEROL AND TRIGLYCERIDES IN WOMEN 
WITH VENOUS THROMBOEMBOLISM
5.1 SUMMARY
:
5.1.1 Plasma concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglyceride and lipoprotein (a) were measured in 62 women who had suffered an 
episode of objectively confirmed venous thromboembolism (VTE) at < 50 years of age, 
and in 98 age-matched female controls. The mean BMI of cases was significantly {p <
.7
0.001) higher than that of controls. Plasma triglyceride and LDL-cholesterol correlated 
directly with BMI, whereas HDL-cholesterol correlated inversely with BMI. Plasma 
triglyceride was significantly higher, and total cholesterol / HDL-cholesterol 
significantly lower, in cases compared to controls. After adjustment for BMI, the 
plasma total cholesterol and LDL-cholesterol remained significantly lower in cases. No 
significant differences in mean plasma lipoprotein (a) levels were identified between 
cases and controls. Lipoprotein (a) does not appear to be significantly associated with 
the development of VTE in young women. The increased risk of VTE in obese subjects 
may be mediated, at least in part, via hypertriglyceridaemia, through its effects on 
levels of coagulation factors, natural anticoagulants, and PAI-1. Furthermore, despite 
increased mean BMI such subjects do not exhibit elevations in LDL-cholesterol 
concentrations. In fact, LDL-cholesterol concentrations may be reduced in subjects 
with a history of VTE. Further studies are required to confirm and elucidate 
mechanisms for these observations.
«
■g
5.2 INTRODUCTION
5.2.1 In contrast to data linking abnormalities of lipid metabolism to the development
of prevalent arterial disease, few studies have examined a possible role for lipids in the
aetiology of venous thromboembolism (VTE). This is perhaps surprising considering
the advances that have recently been made in elucidating the causes of VTE. Inherited
coagulation abnonnalities are presently identified in around 25-30% of individuals
presenting with a first episode of VTE. The factor V Leiden (FVL) and prothrombin
202lOA mutations are the most prevalent genetic defects identified (53,63,85).
Elevated plasma homocysteine is also a common finding in those with VTE, identified
in approximately 10% (102). Furthermore, approximately 20% of individuals with VTE
have persistently elevated levels of coagulation FVIII (> 150 iu/dl), which is associated 
.with a relative risk of VTE of around four-fold (115). Considering FVL, prothrombin 
20210A, elevated FVIII, hyperhomocysteinaemia, and natural anticoagulant 
(antithrombin, protein C and protein S) deficiencies collectively, around 60% of 
subjects with VTE have an underlying thrombophilia, although not all are readily 
demonstrable to be inherited, and some are clearly influenced by enviromnental factors. 
Such thrombophilic abnormalities exert their effects predominantly via prothiombotic 
changes in the coagulation pathway.
3
«Ï
5.2.2 Lipids have complex effects on the coagulation cascade. For example, triglyceride
.
plays a major role in FVII activity in plasma, and has a direct effect on endothelium to 
provoke prothrombotic changes, such as an increased expression of plasminogen 
activator inhibitor type 1 (PAI-1) and von Willebrand factor (214). Triglyceride also 
has effects on endothelial cell adhesion molecules (214). Despite such complex effects
96 t
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of lipids, which may be involved in the pathogenesis of VTE, there is a paucity of data 
in this area. The only published data suggests that individuals with elevated total 
cholesterol levels and / or triglyceride, may be at increased risk of VTE (215,216).
Furthermore, elevated lipoprotein (a), which shares stmctural similarities to 
plasminogen, has been reported as a possible risk factor for puhnonary embolism (PE), 
and for chronic thromboembolic pulmonaiy hypertension (217,218).
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5.2.3 In a study to determine the aetiology of VTE in young women, we investigated 
plasma lipid parameters (total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglyceride, and lipoprotein (a)) in 62 women with a previous episode of objectively 
confirmed VTE at age < 50 years, and in 98 healthy age-matched female controls.
■y:
5.3.2 From an eligible cohort of 161 women with a past history of VTE, 2 had died 
(both from PE), 4 were excluded due to psychiatric disorders, and 84 were either
98
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5.3 PATIENTS, MATERIALS AND METHODS
5.3.1 The study was approved by the local research ethics committee. Women who had
suffered an episode of objectively continued VTE at < 50 years of age and treated in
our unit were eligible for inclusion in the study. Consecutive females who developed
VTE related to pregnancy or up to six weeks post-partum between 1985-1998 were
invited to participate. In addition, consecutive women who presented with VTE to our
hospital between 1993-1997 at age <50 years were invited to participate. Women in 
.whom the diagnosis was related to intravenous drug abuse or cancer were excluded
from the study. For deep vein thrombosis (DVT), the diagnosis was accepted if duplex
Doppler scanning, compression ultrasound, or venography were diagnostic. For
pulmonary embolism (PE) the diagnosis was accepted if the ventilation-perfusion 
.scanning result was of either high or intennediate probability, and they had received at
least six-months of anticoagulant therapy.
untraceable, had moved from our area, or declined participation. In total, 71 women 
agreed to participate in the study. Blood for lipid studies was unavailable in 9 women at 
the time of analysis. Therefore, data is presented on a total of 62 female cases. 
Triglyceride data is presented on 46 female cases, since 16 women had not performed 
an adequate 12-hour overnight fast. No women were current users of hormonal 
preparations or lipid lowering drugs, and none had a personal history of arterial disease.
Height (m) and weight (kg) were recorded. Body mass index (BMI) was calculated
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I5.3.3 Ninety-eight healthy aged-matched female controls, free from arterial and venous 
disease, diabetes mellitus or dyslipidaemia were recruited by local advertisements for 
volunteers in our area. Although not randomly sampled, the distributions of age, 
anthropometric and biochemical data are very similar to those found in general 
population surveys. BMI was recorded in controls, who had blood removed to assay 
lipid parameters. None of the controls were users of lipid lowering drugs or hormonal 
preparations.
5.3.4 Blood collection and sample analysis
5.3.4.1 Blood samples were obtained at least 6 months following the thrombotic event.
None of the cases or controls were pregnant at the time of blood sampling. Blood was 
withdrawn after a 12-hour overnight fast. For lipid analysis, 9ml venous blood was 
collected into tubes containing potassium EDTA as anticoagulant. Plasma was 
collected following centrifugation, and aliquots were frozen and stored at -70  ^C until 
analysis. In addition, 20ml venous blood was added to trisodium citrate (9 parts blood:
1 part anticoagulant) for the purpose of thrombophilia investigation.
5.3.4.2 Plasma cholesterol, triglyceride and HDL assays were perfonned using the 
standard lipid research clinics protocol (219). LDL-cholesterol was calculated using the 
Friedwald fonnula (220). Lipoprotein (a) analysis was carried out on EDTA plasma 
samples by a latex agglutination assay (Innotest Lp(a), Immunogenetics N.V.,
Belgium), which has been shown to have an excellent correlation with a manual 
enzyme immunoassay (R2=97%) in our laboratory (221).
5.3.4.3 Thrombophilia testing was performed in women with previous VTE but not on
f  I
:.....
healthy controls. This included prothrombin time, activated partial thromboplastin time, 
thrombin time, fibrinogen, plasma FVIIIc, antithrombin (AT) and protein C (PC) 
activity, free and total protein S antigens, lupus inhibitor screen (APTT perfonned on a 
mix of four parts patient platelet poor plasma to one part normal platelet poor plasma, 
and dilute Russells’ viper venom test with platelet neutralisation step), IgG and IgM 
anticardiolipin antibody assays and unmodified activated protein C-sensitivity ratio 
(APC-SR). Polymerase chain reaction was used to determine the presence or absence of 
the factor V Leiden (FVL) and prothrombin 202 lOA gene mutations in all cases.
5.3.4.4 Plasma FVIIIc was measured in a one-stage assay. Briefly, 0.1ml dilutions of 
test and standard plasmas were mixed with 0. Imls of F VIII deficient plasma. An APTT 
was perfonned for each dilution and the clotting times plotted on log-log graph paper 
against dilution. The FVIIIc level in the test samples were calculated from the log-log 
plot. The analytical techniques used in the remaining thrombophilia tests have been 
described previously.
5.3.5 Statistical analysis
The significance of differences in mean age, BMI, and lipid values in cases and 
controls were detennined by using the Students t-test. Correlation coefficients 
(Pearson) were calculated to determine the relationship between BMI and lipid 
parameters. Correlation coefficients and regression plots were calculated using Minitab 
(version 11, PA, USA). Significance was taken at the 95% level, p  values are two- 
tailed. Non-parametric data were log-transformed prior to analysis. Multiple linear 
regression was used to adjust for the influence of BMI on the unadjusted differences in 
lipid parameters between groups. Linear regression was performed using Minitab.
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presented with DVT and 16 with PE.
I
5.4 RESULTS
■5.4.1 The characteristics of the 62 cases and 98 controls are shown in table 1. The mean i
JBMI of cases at time of sampling (28.5 ± 6.2) was significantly higher than of controls i(24.3 ± 3.8) (/? <0.0001 ). The mean age at presentation with VTE was 31.2 years (range
■i15-50 years, SD 8.3). Both groups were matched for age at time of blood withdrawal: ®"Imean age at time of blood sampling in cases was 35.8 years (range 16-56) and in 
controls was 37.0 years (range 18-69) {p = NS). Of the 62 women with VTE, 46
5.4.2 Precipitating factors for VTE were as follows: pregnancy (39/62, 63%), combined 
oral contraceptive pill (10/62, 16%), hormone replacement therapy (2/62,3%), surgery
1(1/62), and immobility (1/62). In 9/62 (14.5%) women the event occurred
spontaneously. In 8/62 (13%) women the event was recurrent. Twelve women were on I
oral anticoagulants at the time of blood withdrawal.
5.4.3 We examined the relationship between BMI and total cholesterol, HDL- 
cholesterol, LDL-cholesterol, triglyceride, and lipoprotein (a) concentrations, in cases f
and controls (table 2). There was a significant positive correlation between BMI and 
both triglyceride (figure 1) and LDL-cholesterol in cases and controls. Total cholesterol 
concentration was found to correlate directly with BMI in cases, but not in controls.
HDL-cholesterol correlated inversely with BMI only in controls. No significant 
correlation was observed between lipoprotein (a) and BMI.
5.4.4 In women with a past history of VTE, there were no significant correlations f
observed between triglyceride concentration and fibrinogen (r = 0.13,^ = 0.4), FVIIIc I101
I
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(r = 0.01,^ = 0.9), or APC-SR (r ^  -0.16,/? = 0.32). Furthermore, no significant 
correlation was identified between total cholesterol and fibrinogen (r = 0.1, /? -  0.4),
FVIIIc (r=-0.1,/? = 0.4) or APC-SR (r -  -0.1, /? -  0.5).
I
5.4.5 Mean concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol, 
triglyceride, and lipoprotein (a) in cases and controls are shown in table 1. Mean 
unadjusted total cholesterol {p = 0.02) and LDL-cholesterol (p = 0.01) were 
significantly lower, and triglyceride significantly higher {p = 0.023), in cases compared 
to controls. The unadjusted odds ratio for risk of VTE associated with triglyceride 
concentration > 1 mmol/1 was 2.15 (95% Cl 1.06-4.35). After adjustment for BMI, the 
mean total cholesterol (/?< 0.001) and LDL-cholesterol {p < 0.001) remained 
significantly lower in cases compared to controls, whereas triglyceride levels were not 
significantly different (p = 0.786). Mean HDL-cholesterol was significantly lower in 
cases compared to controls {p = 0.042), though this was not significant following 
adjustment for BMI (p = 0.484). There were no significant differences in mean 
lipoprotein (a) concentration between cases and controls.
:
■’ «a
5.4.6 Thrombophilia screening of cases with a past history of VTE identified 4 (6.5%) 
women with antithrombin deficiency (3 with type I deficiency, 1 with type II 
deficiency), 1 (1.6%) with protein C deficiency, 1 with antiphospholipid syndrome 
(persistently elevated IgG anticardiolipin antibody, 15-44 iu/dl), 5 (8.1%) with FVL (4 
heterozygous, 1 homozygous) and 4 (6.5%) with the prothrombin 202lOA mutation. No 
combined heritable thrombophilias were detected. Plasma homocysteine was not 
measured. The overall prevalence of detectable thrombophilia in the cohort of 62 was 
24.2% (15/62). 15 women had FVIIIc of > 150 iu/dl. Of these women, 1 had protein C
deficiency, 1 had the prothrombin 202 lOA mutation, and 2 had FVL. Twelve women 
were on oral anticoagulants at the time of blood withdrawal. In these women it was not 
possible to accurately assess protein C and protein S levels, and therefore the 
prevalence of these deficiencies may have been underestimated.
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5.5 DISCUSSION
5.5.2 The overall influence of changes in coagulation factors, coagulation inhibitors, 
and expression of tissue factor, which is observed in subjects with
5.5.1 Lipids have wide-ranging effects on haemostasis that could play a role in the
development of VTE. For example, in a large (> 1500 subjects) epidemiological study
1by Lowe et al, triglyceride and total cholesterol were found to directly correlate with
Î
plasma levels of coagulation factors I (women only), VII, VIII (women only), and DC, 
with elevated levels of natural anticoagulants (antithrombin, protein C, protein S), but 
not with elevated coagulation activation markers (222). Furthermore, activated protein 
C sensitivity ratio (APC-SR) is reported to inversely correlate with total cholesterol
•
levels in both sexes, and with triglyceride levels in women (61). Elevated triglyceride
■
concentrations are associated with elevated PAI-1, usually in association with reduced
:HDL cholesterol, fonning part of the insulin resistance syndrome (223). This may be 
mediated via a direct toxic effect by triglyceride on the endothelium (214). Other 
potential prothrombotic influences exerted by lipids include effects on tissue factor Ipathway inhibitor (TFPI), and effects on monocyte expression of tissue factor (TF). It is 
reported that hypercholesterolaemia may produce a decrease in free TFPI (due to the
.relative increase in lipoprotein associated TFPI) (34), with recent data demonstrating -Vi
low levels of heparin-releasable TFPI (a measure of endothelial TFPI) in subjects with 
previous DVT (224). Monocyte expression of tissue factor (TF) is upregulated 
following ingestion of oxidised LDL, which occurs at sites of atheroma (147). Animal 
studies have demonstrated that monocyte-derived TF may trigger thrombosis (225), and S:'Iit is speculated that monocyte-TF may be important in the development of VTE in 1/
■Îsituations of blood stasis (226).
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hypertriglyceridaemia and / or hypercholesterolaemia, on the risk of VTE is unknown. 
There are few data that have examined the role of lipids in the aetiology of VTE. Talbot 
et al documented serum triglyceride and cholesterol levels in 172 subjects with VTE 
and compared values with those obtained in over 200 controls (216). Mean levels of
cholesterol and triglyceride were higher in cases than in controls, although taken
■overall the findings did not reach statistical significance. However, subgroup analysis 
revealed that individuals with recuirent or spontaneous VTE had significantly higher 
serum cholesterol levels compared with controls. Wliilst this study provided an 
interesting observation, unfortunately the diagnosis of VTE was not objectively 
confirmed in many individuals, and the BMI of cases and controls was not detailed.
;
5.5.3 Kawasaki et al have investigated cholesterol and triglyceride levels in 109 
consecutive subjects with DVT and compared their findings with those obtained in age, 
sex and BMI-matched controls (215). The paper did not detail timing of blood samples 
in relation to the VTE event. Hypercholesterolaemia (with or without 
hypertriglyceridaemia) was associated with an increased risk of DVT (odds ratio 4.5, 
95% Cl 2.4-S.3). Hypertriglyceridaemia (vrith or without hypercholesterolaemia) was 
also identified as a risk factor for DVT (odds ratio 2.4, 95% Cl 1.3-4.6). The finding of 
hypercholesterolaemia with hypertriglyceridaemia was associated with the greatest risk 
of DVT (odds ratio 5.1,95% Cl 2-13).
5.5.4 Lipoprotein (a) has recently been the subject of investigation as a potential risk 
factor for VTE. Lipoprotein (a) shares sequence homology with plasminogen, and may 
compete for binding to fibrin, thereby inhibiting endogenous fibrinolysis (227). 
Elevated lipoprotein (a) has been reported in 40 patients with chronic thromboembolic
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pulmonary hypertension (217), and also in 25 subjects with previous pulmonary 
embolism (218). There are currently no data on lipoprotein (a) levels in subjects with 
DVT.
*
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5.5.5 In the present study total cholesterol, triglyceride, HDL-cholesterol, LDL- 
cholesterol and lipoprotein (a) concentrations in women aged <50 years at time of 
VTE, without a personal history of arterial disease, were compared to those obtained in 
healthy age-matched female controls. We found that BMI correlated directly with 
triglyceride and LDL-cholesterol. HDL-cholesterol was inversely conelated with BMI, 
though this was only significant in controls. We found no significant correlation 
between triglyceride or total cholesterol and fibrinogen, FVIIIc or APC-SR, unlike the 
study by Lowe (222). However, it is likely that the number of individuals studied here 
was too small to detect any significant correlations. Unexpectedly, we found that both 
total cholesterol and LDL-cholesterol (unadjusted and following adjustment for BMI) 
were significantly lower in cases compared to controls. Unadjusted triglyceride 
concentrations were significantly higher in cases, reflecting the direct correlation with 
BMI; however, the difference was not significant following adjustment for BMI. HDL- 
cholesterol was significantly lower in cases, though this was not significant following 
adjustment for BMI. There were no significant differences in lipoprotein (a) 
concentration in cases compared with controls. The reason for the lower total and LDL- 
cholesterol levels in cases compared to controls is unknown. We may speculate that 
since LDL catabolism is effected by the LDL-receptor, women with a history of VTE 
may have an increased receptor number or affinity. Alternatively, as LDL-receptor 
regulation is altered by oestrogen status (228), it is conceivable that such women have a 
heightened endogenous oestrogen status or an increased responsiveness to oestrogens.
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This suggestion, however, must remain tentative until further data are available.
5.5.6 We found that the mean BMI of cases was markedly higher than of contiols {p < 
0.001), although we did not record BMI at the time of VTE event. Our control data 
appears representative of the general population, and it therefore seems likely that the 
higher BMI observed in cases is a genuine finding. BMI > 25 kg/m^ is an established 
risk factor for VTE (2,3,6), although the mechanism is unknown. The observation of a 
significantly higher BMI in women with VTE, with associated elevated triglyceride and 
decreased HDL-cholesterol concentrations, is of considerable interest. A pattern of high 
triglyceride and low HDL is a feature of the insulin resistance phenotype syndrome 
(223). As yet, there are no studies that have examined insulin and glucose 
concentrations in subjects with a history of VTE. We hypothesise that the increased risk 
of VTE associated with increasing BMI may be mediated, in part, via 
hypertriglyceridaemia, which is accompanied by elevated coagulation factors, elevated 
PAI-I, increased resistance to the anticoagulant action of APC, and effects on 
endothelial cells. The question of whether the insulin resistance syndrome may be 
associated with a higher BMI in a proportion of individuals with VTE requires further 
research. Although data from Lowe et al (222) demonstrate that the coagulation 
changes observed with increasing triglyceride and / or cholesterol concentrations may 
be negated by increased levels of natural anticoagulants, these effects may be of 
importance in certain circumstances. For example, normal pregnancy is accompanied 
by a significant rise in triglyceride concentration as gestation progresses, which in turn 
is accompanied by a marked increase in FVIIc, PAI-1, and D-Dimers (229,230). 
Furthermore, pregnancies complicated by pre-eclampsia exhibit a more marked rise in 
plasma triglyceride concentration, suggesting that triglyceride may be involved in the
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thrombotic process (231).
5.5.7 We did not observe a significant difference in lipoprotein (a) concentration in 
cases compared to controls. Lipoprotein (a) may be elevated as part of an acute phase 
response (232), and recent data suggests that a proportion of individuals with previous 
VTE demonstrate evidence of inflammation (elevated C-reactive protein) several years 
following the event (117). This may explain the elevated lipoprotein (a) levels in 
subjects with VTE reported by other researchers.
5.5.8 We recognise certain limitations of our study. Our subjects were women who had
developed VTE at < 50 years of age, and therefore represent a relatively select group.
We did'mot measuie coagulation factor levels (other than FVtll), or investigate for
possible insulin resistance, in cases and controls. Our findings raise the possibility that
.elevated plasma triglyceride concentration, with associated effects on coagulation 
,factors, APC resistance, and PAI-1, may be of some importance in the development of
,VTE in subjects with high (> 25 kg/m ) BMI. The higher BMI observed in individuals
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with VTE is unexplained, though may relate (at least in part) to the insulin resistance 
syndrome. Data on a larger number of consecutive subjects with VTE, with 
measurement of lipids, coagulation factors, coagulation inhibitors, and plasma glucose 
and insulin concentration would be of interest. Clearly with such marked effects on the 
coagulation cascade, further data are required to determine the precise role of lipids in 
the aetiology of VTE.
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Table 5.1 Mean (±SD) age at time of blood withdrawal, BMI, and total cholesterol 
(mmo!/l), triglyceride (mmol/1), HDL-cholesterol (mmol/1), LDL-cholesterol 
(mmol/1), and lipoprotein (a) (mg/dl) in 62 women with previous VTE and in 98
■"1;
controls.
Cases Controls Unadjusted Adjusted
(n=62) (n=98) /?“ value /7-value t ■/;
Mean age (±SD) 35.8 (±9.0) 37.0 (±11.5) NS
Mean BMI (±SD) 28.5 (±6.2) 24.3 (±3.8) <0.001 ——
Total cholesterol 4.74 (±0.97) 5.13 (±1.06) 0.020 <0.001
Triglyceride^'^ 1.29 (±0.55)1 1.09 (±0.59) 0.023 0.786
HDL 1.39 (±0.34) 1.44 (±0.35) 0.042 0.484 1
LDL 2.76 (±0.82) 3.18 (±0.95) 0.011 <0.001 »■i
Lp(a)*^ 23.85 (±25.51) 27.5 (±34.5)» 0.473
iit  adjusted for BMI 
J triglyceride data available in 46 cases 
Lipoprotein (a) perfonned on 64 controls
Non-parametric data (triglyceride, lipoprotein (a) concentrations) were 
logarithmically transfonned prior to analysis
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Triglyceride measurements in 46 female cases
I
Table 5.2 Correlation coefficients between BMI and total cholesterol, triglyceride, 
LDL-cholesterol, HDL-cholesterol and lipoprotein (a), in cases and controls.
Total cholesterol Triglyceride^ LDL HDL Lp(a)
Cases (n=62) 0.35} 0.29*» 0.38} -0.20 -0.16
#
Controls (n-98) 0.19 0.471 0.25} - 0.27} 0.04
'is
Significance levels: %p = 0.005, }/> = 0.01, **/? = 0.047, t p  < 0.001
■.JÎ-
■I"■f
Î
■W
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Figure 5.1 Correlation of triglyceride (mmol/1) with BMI in cases.
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CHAPTER 6
PREVALENCE OF THE PGST-THROMBOTIC SYNDROME AND CHRONIC 
VENOUS INSUFFICIENCY IN YOUNG WOMEN WITH VENOUS
THROMBOEMBOLISM 
6.1 SUMMARY
6.1.1 Seventy-one women who had suffered an episode of objectively proven VTE (52 
DVT, 19 PE) at age < 50 years were assessed at a mean of 51 months following the 
event. Subjects were interviewed and examined to determine the prevalence of the post- 
thrombotic syndrome (PTS), and had light reflection rheography (LRR) perfonned on 
both lower limbs to document the prevalence of chronic venous insufficiency. LRR was 
also performed on lower limbs of healthy age-matched female controls. Mild PTS was 
common in women with a previous episode of DVT. Women with a single episode of 
DVT were more likely to demonstrate evidence of venous insufficiency compared to 
healthy age-matched female controls (OR 10.9, 95% confidence interval 4.26-28.0). 
Women with PE were also more likely to have venous insufficiency (OR 3.8, 95% 
confidence interval 1.2-12.3) compared to controls. There was poor correlation between 
symptoms of mild PTS and objectively demonstrated venous insufficiency. However, 
moderate PTS correlated well with LRR findings. Compared with women who had 
suffered a single previous episode of DVT, women with recurrent DVT were more 
likely to develop moderate compared with mild PTS (OR 7.7, 95% confidence interval 
1.3-44.9), and were more likely to have evidence of venous insufficiency. There was no 
apparent increase in PTS or venous insufficiency in women with VTE related to 
pregnancy. 24% of male partners subsequently underwent vasectomy as the preferred 
mode of contraception following VTE.
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6.2 INTRODUCTION
6.2.1 Venous thromboembolism (VTE) appears particularly prevalent in women, being 
2-3 times more common than in men during the reproductive years (9). This may 
largely be attributed to prothrombotic triggers which are experienced by young women, 
such as the combined oral contraceptive pill and pregnancy. Whilst only a small 
proportion of individuals who experience an episode of treated VTE die as a result, 
there are few data on the long-tenn consequences amongst survivors. There are 
undoubtedly restrictions on future contraceptive choice, since most clinicians would not 
prescribe the combined oral contraceptive pill to women with a history of VTE. In 
addition, it is recognised that a variable proportion develop the post-thrombotic 
syndrome (PTS) (postphlebitic syndrome), a term used to describe continuing pain, 
swelling, discoloration, varicosities or ulceration in the previously thrombosed limb. 
Data suggest that relatively minor symptoms of PTS are common after an episode of 
VTE (20,21,233-236). However, there are few data on the prevalence of this syndrome 
in young women with previous VTE. Data on a small number of women with VTE 
related to pregnancy suggest a higher prevalence of subsequent PTS compared with 
women who experience VTE in relation to other triggers (237).
6.2.2 It is unclear if symptoms of PTS correlate with objective evidence of chronic 
venous insufficiency. For example, minor symptoms such as leg pain or leg cramps are 
common following DVT, and may relate either to venous insufficiency or equally could 
be psychological in origin. Ambulatory venous pressure monitoring is regarded as the 
gold standard to demonstrate venous insufficiency (238). However, it is an invasive 
procedure requiring considerable expertise. Light reflection rheography (LRR) is a 
simple and reproducible technique which may be used to provide objective evidence of
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venous insufficiency (238-240). In previous studies it has demonstrated excellent 
correlation with ambulatory venous pressure monitoring (238).
6.2.3 The aims of our study were to document the prevalence of symptoms and signs of 
PTS in women with a previous episode of VTE at age < 50 years, to determine the
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prevalence of venous insufficiency in this group and compare this to age-matched 
female controls, and to determine if venous insufficiency / PTS correlated with 
precipitating factors for VTE (pregnancy versus non-pregnancy), time from event, 
number of events, or body mass index. We also documented the contraceptive choices 
made by women who had experienced their episode of VTE during the childbearing
t
years.
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6.3 PATIENTS. MATERIALS AND METHODS
6.3.1 A total of 71 women who had suffered an episode of objectively confimied 
symptomatic VTE (either deep vein thrombosis or pulmonary embolism) at age < 50 
years were the subject of study. In ail cases DVT had been diagnosed by compression 
or Doppler ultrasound, or by venography; in the case of pulmonary embolism, the 
diagnosis was accepted if V/Q scan was of either high or intermediate probability and 
the patient received anticoagulation for at least six months. Patient characteristics are 
presented in table 1. Female cases were recruited from two sources. First, from a cohort 
of 87 consecutive women with VTE related to pregiancy or the puerperium between 
1985-1997 at two nearby maternity units, 45 agreed to participate in a retrospective 
follow-up study to determine the long-term outfcome of VTE. The remainder of this 
pregnancy related VTE cohort were either untraceable, declined participation or lived 
an unacceptable distance from our unit. Second, an additional 26 unselected women 
were recruited from a cohort of 74 consecutive women who had suffered an episode of 
objectively confirmed VTE aged < 50 years at our hospital between 1993-1997. From 
this cohort of 74, two died from PE, 4 were excluded due to psychiatric disorders, and 
42 were either untraceable, declined participation or lived an unacceptable distance 
from our unit. Of the 26 who participated, 10 had suffered spontaneous VTE, 10 were 
associated with COCP, 2 associated with HRT, 2 associated with surgery and 2 were 
associated with immobility. Women who had cancer or in whom the episode of VTE 
was related to intravenous drug abuse were excluded from the study.
6.3.2 All of the participants underwent physical examination to evaluate symptoms and 
signs of PTS. Women were asked about symptoms of PTS (residual pain or cramps), 
and were examined by a doctor for evidence of venous insufficiency (limb swelling,
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skin discoloration, skin hyperpigmentation, varicose veins, ulceration in the previously 
thrombosed limb). PTS was classified using a simplified version of a validated scoring 
system (241). We graded PTS as absent (asymptomatic), mild (residual pain or minimal 
swelling), moderate (skin discoloration, skin hyperpigmentation, major limb swelling, 
development of varicosities), or severe (healed or acute ulceration). Cun ent use of 
compression stockings was recorded. Contraceptive choice after the event was recorded
those under 40 years. In all participants, height (m) and weight (kg) were recorded to 
calculate BMI (kg/m^). Healthy age-matched female controls, without history of VTE 
or venous disease, were recruited to determine the prevalence of asymptomatic venous 
insufficiency (using LRR) in a young healthy female population.
in those who suffered VTE related either to pregnancy, the oral contraceptive pill, or
I
.1
6.3.3 Light Reflection Rheography (LRR)
6.3.3.1 The light reflection rheography (LRR) instrument {AVI000, Haeinodynamics,
Cheshire, UK) consists of an electronic sensor head and a combined amplifier-recorder.
The sensor head contains three light-emitting diodes that transilluminate the skin to a 
depth of 0.5-1.5 mm. The emitted light is either absorbed by erythrocytes within the
-•
deimal microcirculation, or reflected back to the photodetector on the sensor head. The 
intensity of reflected light is translated into an electrical signal, which is recorded on a 
strip chart. The LRR curve, therefore, graphically illustrates dennal blood content. LRR 
can quantify both parameters of venous function, namely venous emptying and venous 
refill time (see appendix 4).
%!:
6.3.3.2 All LRR traces were recorded with the patient seated in a chair with both feet
.flat on the floor. Skin temperature was assessed by means of a thermistor probe located
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within the sensor head. Patients with extremes of skin temperature (outside the range 28 
to 32  ^C) were excluded from examination at that time. The LRR sensor head was 
affixed 10cm above the medial malleolus by means of a double-sided adhesive ring. 
After a period of approximately one-minute to allow for calibration, each patient 
performed 10 dorsiflexions of the foot over a period of 15 seconds (this corresponds to 
the venous emptying phase on the tracing). The LRR has a metronome, which emits 
optical and acoustic signals, helping the patient with the exercise regimen. The patient 
was then instructed to rest the foot, and the instrument continued tracing for a further 
40 seconds (venous refill time).
6.3.3.3 LRR was perfonned on both left and right lower limbs of cases and controls. 
LRR traces were interpreted by an individual with experience of the technique, who 
was blind to patient identity and symptomatology (IAG). Venous refill times (VRT) of 
less than 25 seconds were considered indicative of venous insufficiency, as previously 
described (239,240). We categorised tracings into those which were either nonnal 
(VRT > or equal to 25 seconds) and those which were abnonnal (VRT < 25 seconds).
6.3.4 Statistical techniques
6.3.4.1 The significance of differences between mean age at follow-up, follow-up 
intervals, and BMI were determined using the Students t-test (196). All p  values are 
two-tailed. We calculated odds ratios (OR) with 95% confidence intervals as estimates 
of the relative risk of development of PTS and venous insufficiency. 95% confidence 
intervals were calculated according to Woolfs method (Chapter 3). An OR was 
considered to be statistically significant when the lower limit of the 95% Cl was > 1.0. 
Correlation coefficients (Pearson) were calculated to determine the relationship
117
between LRR venous refill time and BMI. Correlation coefficients and regression plots 
were calculated using Minitab (version 11, PA, USA).
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6.4 RESULTS
6.4.1 Symptoms and clinical signs of PTS
6.4.1.1 Of 71 women evaluated for the PTS, 43 had suffered from a single episode of 
deep vein thrombosis (DVT), 9 from recurrent DVT, and 19 from clinically isolated
diagnosis, were largely asymptomatic (79%) for PTS. Control subjects gave no
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pulmonary embolism (PE). The mean age at follow-up of the whole group was 35.5
years (range 16-56). There were no significant differences in age at follow-up between
those with DVT or PE. Mean follow-up interval (time from event to interview) was
51.4 months (range 6-156). The mean follow-up interval in women with DVT (56.7 
months) was significantly longer than those with PE (38.9 months) (p < 0.05, table 6.1). 
Cases had a significantly higher BMI (28.4) compared with controls (25.6) (p < 0.005). 
9/71 (12.7%) women, of whom 8 had symptoms of PTS, were using compression 
stockings at the time of follow-up.
6.4.1.2 None of the cohort had severe PTS by our grading. Of 43 women with a single 
previous episode of DVT, 11 (25.6%) were asymptomatic for PTS compared with none 
of the group with recurrent DVT (table 6.2). The majority of women with a single 
episode of DVT had mild PTS (29/43,67.4%). Moderate PTS occurred in 3/43 (7%)
women with single DVT but in 4/9 (44.4%) women with recurrent DVT. Women with
.:;rrecurrent DVT were more likely to develop moderate compared to mild PTS (OR 7.7, 
95% confidence interval 1.3-44.9) in comparison to women with a single episode of Î
DVT. Women presenting with PE, who had no symptoms or signs of DVT at time of
symptoms to suggest possible PTS.
i
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6.4.2 Light Reflection Rheography
6.4.2.1 LRR was performed on both lower limbs of 68/71 women (49 DVT, 19 PE). 
LRR was not performed in 3 women, all of whom had previously suffered DVT, due to 
paraparesis (1), pregnancy (1), and technical difficulty (1). LRR was also performed on 
both lower limbs of 68 age-matched female controls with no previous history of venous 
disease (table 1).
6.4.2.2 VRT was < 25 seconds, indicating venous insufficiency, in 33/49 (67.3%) 
women with previous DVT (55% in the previously thrombosed leg, 33% bilaterally, 
and 12% in the contralateral limb only). Women with a single episode of DVT who 
were evaluated by LRR (n = 40) had a prevalence of venous insufficiency of 62.5% 
(25/40) in either limb. In women with recurrent DVT (n = 9), the prevalence of venous 
insufficiency in either limb was 88.9% (8/9). 7/19 (36.8%) women with previous PE 
had evidence of venous insufficiency by LRR (either limb). The overall prevalence of 
venous insufficiency (as demonstrated by LRR) in the contralateral limbs of women 
with previous DVT (those with bilateral abnormalities plus those with isolated 
contralateral limb abnonnalities) was 22/49 (45%). Among controls, 9/68 (13%) had a 
VRT < 25 seconds (7 with an abnormal tracing in one limb, 2 with bilateral 
abnormalities). Women with a single episode of DVT were significantly more likely to 
demonstrate evidence of venous insufficiency (in any limb) compared to controls (odds 
ratio 10.9, 95% confidence interval 4.26-28.0). Women with PE were also more likely 
to have venous insufficiency (odds ratio 3.8, 95% confidence interval 1.2-12.3) 
compared to controls. The odds ratio for abnormal LRR in all VTE (DVT plus PE) 
compared with controls was 9.4 (95% confidence interval 4.0-21.8).
120
121
■y-
6.4.2.4 Clinical symptoms and signs of PTS were correlated with LRR evidence of
.venous insufficiency (table 6.3). In women with previous VTE, venous insufficiency 
was almost as frequent in those asymptomatic for PTS compared to those with 
symptoms / signs of mild PTS. However, LRR was consistently abnormal in 5/6 
women with moderate PTS. One patient with moderate PTS who had normal LRR 
tracings also had Milroys disease, an inherited lymphoedematous condition resulting in 
significant limb swelling. In this patient it was difficult to differentiate between 
symptoms related to previous DVTand those related to lymphoedema. The normal LRR 
tracings suggest the latter.
6.4.3 PTS / LRR in women with DVT related to pregnancy
6.4.3.1 We perfonned subgroup analysis to detennine if symptoms / signs of PTS, or 
chronic venous insufficiency, were more common in women in whom DVT was related 
to pregnancy. From our cohort, 28 women were identified who had suffered a single 
episode of DVT related to pregnancy. We also identified 15 women who had suffered a 
single episode of DVT um elated to pregnancy. There were no significant differences in 
mean age at follow-up (33.8 ± 8.9 years versus 38.3 ± 9.65 years,/? >0.1) or mean 
follow-up interval (61.5 ± 39.8 months versus 41.9 ± 17.1,/? > 0.05) in either group.
Table 6.4 shows that the prevalence of mild and moderate PTS, and of venous 
insufficiency (in any limb), was similar in both groups, suggesting that women who 
suffer a DVT related to pregnancy are not more likely to develop PTS or venous 
insufficiency compared to women in whom VTE is unrelated to pregnancy
4
6.4.4 PTS / Venous insufficiency in relation to time from event
6.4.4.1 Symptoms, clinical signs, and objective evidence of chronic venous 
insufficiency (CVI) were examined in relation to time from event (table 6.5). There was 
no clear pattern observed either in prevalence of symptoms / clinical signs of PTS, or 
evidence of CVI, in relation to time from event. However, moderate PTS was only 
observed when at least 2 years had elapsed since the event.
6.4.5 Effect of BMI on development of PTS and Venous insufficiency
6.4.5.1 We examined the effect of BMI on PTS grading in 40 women with a prior 
single episode of DVT. Table 6.5 shows that there was no overall clear effect of BMI 
on grading of PTS. We also assessed the relationship between BMI and LRR refill 
times in these women. We compared LRR refill times recorded in either the left or right 
leg (depending on the site of thrombosis) and correlated this with BMI. Overall, the 
correlation coefficient was not statistically significant (r = -0.18,/? = 0.28), although 
subgroup analysis demonstrated that BMI correlated inversely with left leg refill time in 
26 women with a previous left leg DVT (r = -0.41,/? = 0.038) (figure 6.1). Amongst 68 
female controls in whom LRR measurements were performed, we found no correlation 
between BMI and venous refill time in either the left (r = -0.08, p  = 0.55) or right
(r = -0.01,/? = 0.97) leg.
6.4.6 Contraceptive choices foHowing VTE
6.4.6.1 Sixty-three women whose episode of VTE was related to pregnancy (n=45), 
oral contraceptive pill (n=10), or in whom the event occurred under 40 years (n=8) 
were asked about contraceptive choices made after VTE. Results are presented in table 
6.7. 19% reported that contraception had not been an area of difficulty since they had
1 2 2
not been sexually active since the event. However, in 24% of cases male partners had 
undergone vasectomy and in 9.5% women had been sterilised. 11% had used or were 
current users of the progesterone-only contraceptive pill. No women subsequently used 
the combined oral contraceptive pill.
II
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6.5 DISCUSSION
6.5.1 This retrospective study of 71 women who suffered VTE at age <50 years 
demonstrates that mild PTS is common in those with previous DVT. Moderate PTS 
was particularly likely to occur in women with recurrent DVT. In contrast, women who 
had suffered a previous episode of PE (unaccompanied by symptoms or signs of DVT) 
were largely asymptomatic for PTS. However, a degree of caution in interpretation of 
these findings is required, since women with previous PE were followed-up at a mean 
shorter interval from diagnosis compared to those with previous DVT. Also, the 
retrospective nature of our study inevitably introduces a degree of selection bias, since 
women with continuing symptoms may be more likely to participate than women who 
are asymptomatic.
6.5.2 The majority of data reporting the long-term outcome of VTE relate 
predominantly to older subjects. Such data suggests that PTS is common in those with 
previous DVT (20,21,233-236). However, the prevalence of PTS appears to vary 
widely, with 29%~79% describing symptoms (21,233-236). This variability may relate 
to the heterogeneous cohorts that are presented. Data also suggests that symptoms of 
PTS may increase with time (235,236). There are few data on the prevalence of PTS in 
young women with previous VTE. Recently, Biguzzi et al followed-up 51 women who 
had experienced DVT before the age of 40 years at a median of 47 months, and found 
mild PTS in 55%, moderate PTS in 4% and severe PTS in 4% (242). Bergqvist et al 
assessed the prevalence of PTS symptomatology by means of a questionnaire in 104 
women with VTE relaied to pregnancy (243). In keeping with our findings, mild PTS 
was cormnon in this group: only 22% were asymptomatic at median follow-up of 11 
years, and few (4%) had symptoms conesponding to severe PTS. The women in this
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study were not assessed for evidence of venous insufficiency. Lindhagen et al assessed 
23 women following an episode of DVT related to pregnancy and reported PTS in 35% 
(237). In this study 65% of previously thrombosed limbs had evidence of venous 
insufficiency. The authors concluded that women with pregnancy-related DVT 
appeared more likely to develop venous insufficiency compared to women with DVT 
unrelated to pregnancy, despite such small numbers examined and absence of a 
comparison group. Our data does not support this idea. We compared women who had 
suffered a single episode of DVT, either related or unrelated to pregnancy, matched for 
age and time from event, and found that the prevalence of mild and moderate PTS was
similar in both groups. Furthermore, the prevalence of objectively confirmed venous 
insufficiency was similar in both groups. The numbers involved in our comparison are 
small, however, and larger numbers of patients are required to confirm this data.
6.5.3 We used the technique of LRR to objectively demonstrate venous insufficiency.
This technique is easy to learn, non-invasive, and the traces obtained may be assessed
quantitatively. In addition, the equipment is portable. LRR has been extensively used as
a technique to exclude acute DVT, with a high negative predictive value (244-249).
.LRR has also been used in parallel with invasive venous pressure monitoring in the 
investigation of venous disease, with excellent correlation (238). Using LRR, we 
demonstrated objective evidence of venOus insufficiency in 67% women with previous 
DVT (in 55% of previously thrombosed limbs and in 45% of contralateral limbs) and in
31.8% of women with previous PE. In women with a single episode of DVT evaluated 
by LRR the prevalence of venous insufficiency was 62.5% in either limb, and 88.9% in
I'::-
women with recurrent DVT. Amongst 68 age-matched female controls, free from 
symptomatic venous disease, venous insufficiency was found in 13%. We did not
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perforai LRR on one patient with previous VTE who was pregnant, since pregnancy is 
associated with a significant reduction in velocity of venous flow, particularly in the 
left leg (178). Women with a single episode of DVT were more likely to demonstrate 
evidence of venous insufficiency (in any limb) compared to controls (odds ratio 10.9, 
95% confidence interval 4.26-28.0). Women with PE were also more likely to have 
venous insufficiency (odds ratio 3.8, 95% confidence interval 1.2-12.3) compared to 
controls.
6.5.4 We observed poor correlation between symptoms of mild PTS and objective 
evidence of venous insufficiency (table 6.3). Many women without symptoms or signs 
of PTS had evidence of venous insufficiency, and a large number who had symptoms 
of mild PTS did not have objective evidence of insufficiency. This may indicate that a 
proportion of cases of mild PTS are not related to venous insufficiency, but could relate 
to other factors (for example, psychological or musculoskeletal). It would appear that 
LRR is not useful in elucidating the cause of mild post-thrombotic leg symptoms. 
However, women with moderate PTS generally had objective evidence of venous 
insufficiency. One woman with “moderate” PTS also had gross lymphoedema; in this 
patient it was impossible to detennine the origin of her symptoms. She had no evidence 
of venous insufficiency using LRR, suggesting that lymphoedema may be the major 
cause of her symptoms. The explanation for the high prevalence of venous 
insufficiency in the contralateral limbs of women with previous VTE is unknown. 
Asymptomatic contralateral thrombosis is not uncommon in those with DVT, providing 
a possible explanation (250). Also, venous insufficiency is itself a risk factor for the 
development of VTE, and we may hypothesise that in a proportion pre-existing venous 
insufficiency contributed to the development of subsequent VTE.
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6.5.5 In the study by Biguzzi et al, 51 women with previous DVT were assessed for 
evidence of venous insufficiency by an alternative technique (colour Doppler 
ultrasound) (242). Almost 30% had evidence of superficial vessel reflux; a further 14% 
had evidence of suboptimal venous recanalisation. No comment was made regarding
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evidence of deep vessel reflux in tliis cohort, which may explain the higher prevalence 
of venous insufficiency detected in our study. This is supported by a study of 386 
patients with venous insufficiency, in which deep venous insufficiency was identified
more frequently than superficial insufficiency (240). In keeping with our findings, the
study of Biguzzi et al reported poor correlation between evidence of venous 
insufficiency and symptoms of PTS (242). Other researchers employing objective
techniques have reported venous insufficiency in 36%-79% of individuals with
previous DVT (21,234,251). We examined the relationship between time from event to
follow-up to determine if venous insufficiency increased in prevalence with time; we
found no evidence of this, in contrast to other studies (236,252). At odds with the study
of Biguzzi et al ((242)), we found no overall relationship between BMI and subsequent
development of PTS. We demonstrated an inverse correlation between BMI and LRR
refill time in women with a previous DVT of the left leg, suggesting that the
development of venous insufficiency in this group may relate, at least in part, to BMI.
This finding should be interpreted with caution, since the numbers involved are
relatively small, and when DVT of the left and right leg were considered collectively,
the correlation coefficient was not statistically significant. Further research would be 
.worthwhile in a larger group of patients. No correlation was observed between BMI 
and refill time in controls.
I
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6.5.6 There are no data on contraceptive choices made by young women following an 
episode of VTE. We found that male vasectomy was a common mode of contraception 
following the event (24%). 9.5% of women underwent surgical sterilisation, which is 
perhaps suiprising when one considers that the operation may increase the risk of 
recurrent VTE. No women were prescribed the combined oral contraceptive. However,
11% had used the progesterone-only pill following their thrombotic event. There are no 
published reports of an association between this form of oral contraception and 
development of VTE. Unfortunately, our contraceptive data is uncontrolled, since 
contraceptive use was not recorded in age-matched female controls. In a future study it 
would be of interest to record such data in age-matched thrombosis-free women for the 
purposes of comparison.
6.6.7 In summary, our study provides important evidence that both symptoms and signs 
of chronic venous insufficiency are common in young women following an episode of 
symptomatic DVT. Young women with VTE, by virtue of their youth, have a long 
period to develop venous insufficiency. In this cohort it will be of interest to
.prospectively monitor for the development of more severe grades of PTS, particularly 
in those with objective evidence of venous insufficiency.
'I
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Table 6.1 Mean age (SD), BMI (SD) (kg/m^) and follow-up (SD) interval in cases 
and controls
Cases Controls
All VTE DVT PE
Number 71 52 19 68
Mean age at follow-up 35.7 (8.9) 35.6(8.8) 35.6 (8.7) 35.5 (9.8)
Mean follow-up interval 51.4 (35.5) 5 6 .f  (37.4) 38.9^ (27.2) -
Mean BMI 28.4^ - (6.4) 27.4 (5.6) 29.9 (7.3) 25.6* (4.8)
I
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Significance levels:  ^p  <0.05 for follow-up interval between DVT and PE 
:|: p  < 0.005 for difference between mean BMI of all VTE and controls 
p  < 0.02 for difference between mean BMI of all PE and controls.
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Table 6.2 Prevalence of post-thrombotic syndrome in 71 women with previous 
VTE. .
j Of, WMi«WiaEitisttaaeai.JwtgggigE»oMB«gNumber / PTS grade Single DVT Recurrent DVT PE
43 9 19
Absent 11 (25.6%) 0 15 (79%)
Mild 29(67yM4) 5 (55.6%) 4(2P%)
Moderate 3(7%) 4f (44.4%) 0
Severe 0 0 0
t  odds ratio for moderate Vs. mild PTS in those with recurrent DVT 7.7,95% Cl 1.3- 
44.9.
'
aI.sa:
130
'■'as
Table 6.3 Correlation of clinical PTS with objective evidence of venous 
insufficiency in 68 women with VTE.
PTS grade LRR abnonnal LRR noraial
   ....................Absent (n=26) 14 (54%) 12 (46%)
Mild (n=36) 21 (58%) 15 (42%)
Moderate (n=6*) 5(83%) 1(17%)
Severe (n^O)
' One patient with moderate PTS also had Milroys disease, an inherited 
lymphoedematous condition resulting in significant limb swelling.
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Table 6,4 Comparison of PTS / Venous insufficiency in women with a single 
episode of DVT related / unrelated to pregnancy.
PTS/LRR Pregnancy-related DVT (n=28) DVT unrelated to pregnancy (n=15)
Absent 7 (25%) 4 (26.7%)
Mild 20 (71.4%) 9 (60%)
Moderate 1 (3.6%) 2 (13.3%)
LRR abnormal 18 (64%) 10 (66.7%)
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Table 6.5 Correlation of PTS symptoms and LRR findings with follow-up interval 
in 68 women with VTE.
Follow-Up n Absent Mild Moderate Venous insufficiency by
interval LRR
Up to 1 yr 12 6 (50%) 6 (50%) 0 8 (67%)
1-2 yrs 11 2(18%) 9 (82%) 0 5 (45%)
2-3 yrs 4 2 (50%) 1 (25%) 1 (25%) 4(100%)
3-4 yrs 10 4 (40%) 5 (50%) 1 (10%) 8 (80%)
4-5 yrs 9 4 (44.5%) 4 (44.5%) 1(11%) 4 (44%)
5-6 yrs 12 5 (42%) 6 (50%) 1 (8%) 5 (42%)
> 6 yrs 10 3 (30%) 5 (50%) 2 (20%) 6 (60%)
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Table 6.6 Influence of BMI on PTS grading in 40 women with a single prior 
episode of DVT.
BMI Number PTS grade 
Absent Mild Moderate
<24 13 2 (15%) 10 (67%) 1(8%)
24-26 9 4 (44.5%) 4 (44.5%) 1(11%)
26-28 6 2 (33%) 3 (50%) 1 (17%)
28-30 6 1 (17%) 5 (83%) 0
>30 6 2 (33%) 4 (67%) 0
"3
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Table 6.7 Contraceptive choices made by 63 women following an episode of VTE
Number >t:j^ .4iie«i»s4sifSU»Bsrs*wwOTE5«W3*S'!KM**i^ ;*^ WSrîmContraceptive choice s
Partner had vasectomy 15 (24%)
Patient sterilised 6 (9.5%) J
Condoms 16 (25.5%) 1;
asProgesterone-only pill 7(11%) 1
lUCD 5(8%)
■
Diaphragm / cap 2(3%0 1e
not sexually active 12(1()%4) a
1
I
4i
1
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Î
1
11Î
135
Figure 6.1 Correlation of left leg venous refill time with BMI in 26 women 
with a prior episode of left DVT.
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CHAPTER? 
7.1 CONCLUSIONS AND FURTHER RESEARCH 
7.1.1 Summary of findings and further research from Chapter 2
7.1.1.1 Our data on risks for VTE in women in the West of Scotland (Chapter 2) has 
highlighted pregnancy and intravenous drug abuse (IVDA) as prevalent triggers for 
thrombosis. In women < 40 years, 67% of all episodes of VTE were associated with 
either pregnancy or IVDA. IVDA may be the most common risk factor for VTE in our 
area in women, since a large number of clinically diagnosed events were also noted. 
DVT related to IVDA was not associated with clinical evidence of PE in any women. A 
future study to determine the prevalence of IVDA as a risk factor for VTE in both sexes 
would be of interest. Such data would help determine the overall contribution of IVDA 
to VTE in our area, and provide further infonnation on risk of symptomatic PE in this 
group. Such data may be liable to bias, since a large number of patients who are drug 
abusers self-discharge from hospital without follow-up, possibly imderestimating the 
risk of PE observed. However, it is likely that symptomatic PE would precipitate re- 
admission to hospital. This gioup of subjects would largely be unsuitable for a 
prospective study involving routine lung scanning to determine the prevalence of 
asymptomatic PE, because of problems with compliance and venous access. Data où 
risk of symptomatic PE in DVT associated with IVDA would be of value, since there is
uncertainty regarding the optimal duration of anticoagulation in this group.'
II
IS7.1.1.2 Data from Chapter 2 identified two women who were users of hormone 
replacement therapy (HRT) at the time of postoperative VTE. There are no data on risk 
of postoperative VTE in users of HRT compared to non-users. This raises the potential
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for a case-control study: all cases of postoperative VTE identified in Chapter 2 
(excluding those with active cancer) would be recalled and interviewed. Specific 
enquiry regarding the use of HRT at the time of surgery would be made. Age-matched 
female controls, free from venous thrombosis, would be selected and matched for BMI 
and surgical procedure. The prevalence of HRT use in cases would be compared to 
their use in controls to determine the risk of postoperative thrombosis in users of HRT.
I
7.1.2 Summary of findings and further research from Chapter 3
7.1.2.1 In Chapter 3 we derived data on the incidence of objectively confirmed DVT 
.and PE associated with pregnancy. The incidence of DVT was 0.68 per 1000 
maternities (95% Cl 0.51-0.85) with 0.47/1000 occurring in the antenatal period (95%
Cl 0.33-0.61) and 0.21/1000 in the puerperium (95% Cl 0.12-0.3). The incidence of PE ■Iwas 0.25 per 1000 maternities (95% Cl 0.15-0.35), 0.1/1000 antenatal (95% Cl 0.04- /
0.16) and 0.15/1000 in the pueiperium (95% Cl 0.07-0.22). However, the puerperal 
event rate was significantly higher for both DVT (18.5/10 000 versus 6.4/10 000) and 
PE (13.0 versus 1.3/10 000). This data is based upon > 90 000 maternities and
represents the largest study of confirmed VTE events related to pregnancy in the
literature. Clinical risk factors during pregnancy were common in women with VTE.
Antithrombin deficiency was identified as a particularly high-risk thrombophilia for
maternal VTE. The factor V Leiden and prothrombin 2021 OG~>A mutations were
.associated with a modest increase in risk of VTE. Women were not investigated for
hyperhomocysteinaemia as part of our study, since the technique was not established in 
our centre at the time of our investigations. There are no data regarding homocysteine 
levels and complications of pregnancy. Ideally, homocysteine should be measured at or 
near the time of a pregnancy event, since nutritional status (folate, B12) plays an
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important role in determining plasma homocysteine levels. In relation to maternal VTE, 
this approach would be impractical due to the low incidence of the condition. However, 
other fetomatemal complications, such as pre-eclampsia or intrauterine growth 
retardation (lUGR), which may be thrombotic in origin, and which are more common 
than maternal VTE, would be ideal for such a study. For example, it would be of 
interest to measure fasting plasma homocysteine, serum folate and detennine MTHFR 
genotype in consecutive women with lUGR, and compare the results to those obtained 
in age- and gestation-matched healthy pregnant controls.
7.1.3 Summary of findings and further research from Chanter 4
7.1.3 In Chapter 4 we detennined the incidence of matenial superficial vein thrombosis 
(SVT) (0.68/1000 maternities, 95% Cl 0.48-0.88), comparable to the incidence of 
maternal DVT. The incidence of SVT in the early post-partum period (0.54/1000 
maternities) was higher than in the antenatal period. None of these women had a 
previous history of deep vein thrombosis or pulmonary embolism, and of those 
followed-up (n=24/47), none had developed DVT or PE after a mean period of four 
years. The risk of SVT was increased, though not significantly, in carriers of the FVL 
mutation (OR 1.83; 95% Cl 0.2-16.4). None of the cohort was screened for the 
prothrombin 20210 mutation. Further investigation into SVT may well be limited by 
the relatively poor follow-up rate. Women may perceive this condition as relatively 
minor, and motivation to participate in a research project to investigate this may be low.
7.1.4 Summary of findings and further research from Chapter 5
7.4.1 Our study of lipid parameters in women with VTE (Chapter 5) showed that 
triglyceride concentrations were significantly higher, and total cholesterol, LDL-
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cholesterol, and HDL-cholesterol significantly lower, in cases compared with controls.
The elevated triglyceride and lower HDL-cholesterol reflect the higher mean BMI of 
women with VTE. This phenotype is similar to that seen in the insulin resistance 
syndrome. The reason for the lower LDL-choIesterol concentrations is unknown. The 
increased risk of VTE associated with increasing BMI may be partly mediated via 
hypertriglyceridaemia, which is accompanied by elevated coagulation factors (and 
inhibitors), increased resistance to the anticoagulant action of APC, and elevated PAI-I.
The insulin resistance syndrome may be associated with the higher BMI seen in some 
individuals with VTE. A large prospective study of consecutive subjects with VTE, 
incorporating measurement of lipids, coagulation factors, coagulation inhibitors, and 
plasma glucose and insulin concentration (as measures of insulin resistance) would be 
of interest to elucidate this area further.
■#
7.1.5 Summary of findings and further research from Chapter 6
7.1.5.1 Our data on the prevalence of the post-thrombotic syndrome (PTS) and chronic 
venous insufficiency (CVÏ) has shown that, among 71 women with a previous episode 
of VTE at age < 50 years, symptoms of PTS were common at a mean 51 months after
the event. Most women with a single previous episode of DVT (n = 43) had mild PTS 
(67.4%); 7% were of moderate severity. In this group the prevalence of venous 
insufficiency was 62.5%. Women with a single previous episode of DVT were 10.9
,times more likely to demonstrate objective evidence of CVI compared vGth age-
matched female controls. There was poor coiTelation between PTS grading and LRR 
.findings, with the exception of moderate grade PTS. This may indicate that a 
.proportion of cases of mild PTS are not related to venous insufficiency, but could relate
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grades of PTS with our findings, which are retrospective, and therefore subject to a
to other factors (for example, psychological or musculoskeletal). Women with recurrent 
DVT (n = 9) appeared more likely to develop moderate PTS (44%), although the 
numbers were small. Symptoms suggestive of PTS were uncommon in women with 
previous PE without clinical evidence of DVT at presentation. We did not observe a 
higher prevalence of PTS or CVI in women with previous pregnancy-related VTE 
compared to women in whom VTE was related to other thrombotic triggers. PTS / CVI
showed no relationship to BMI, although left leg LRR refill time con-elated inversely
with BMI in women with a previous left leg DVT. This correlation was observed in 26
women. A larger prospective study of consecutive subjects with a first confirmed
episode of DVT would be of interest, with measurement of BMI and LRR to detennine 
.if this correlation is confinned. Whilst taking considerably longer to perfonn, a 
prospective study would also be of value to compare the prevalence of the various
.1:
degree of selection bias.
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APPENDIX 1
Data extracted from patient case-notes.
Data Notes
Name
Date of biitli
Address
Year of event
Diagnosis DVT-left DVT-right DVT-bilateral
Definite PE Probable PE
Radiological investigation employed Compression / doppler ultrasound
V/Q scan Spiral CT Pulmonary angiogram
Otlier (specify)
Risk factor(s) COCP (state preparation)
HRT (state prepar ation)
Pregnancy - trimester or puerperium
Surgeiy (within one month of event)
Innnobilily (specify)
Active Cancer
IVDA
Significant medical illness
Nil
Treatment Hepaiin / warfaiin (state duration)
Previous VTE
Outcome Deatli (Y or N)
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APPENDIX 2
PATIENT INFORMATION LEAFLET
Research Project investigating causes of blood clots
Some time ago you were treated for a blood clot which occurred in either the leg or the 
lung. The Haematology departments at both Glasgow Royal Infirmary and the 
Southern General hospitals have been active in researching the causes of Such clotting 
problems. Your clot may have followed, for example, pregnancy, an operation or 
illness, or may have been related to a honnone preparation. We are now able to test for 
certain clotting tendencies, and as part of our research we would like to find out how 
commonly these tendencies occur in women with clots. We are also interested in 
finding out how often the affected leg continues to give trouble when there has been a 
previous clot in the leg.
We would be grateful if you are able to help us in our research. We are holding a series 
of special clinics at Glasgow Royal Infirmary for research into the causes and effects of 
blood clots. At this visit (which will last about 20 minutes) we will
• Ask you some questions about your general health and in particular about your legs 
(for example, sore legs, swollen legs, varicose veins),
• Assess the veins of the leg using a special instrument which is placed on your calf 
(a bit like an ultrasound scan; this is not painful, does not involve any injections and 
only takes about 10-15 minutes). This test cannot be performed through tights, so 
the wearing of trousers would be preferable.
• Obtain a blood sample to check your blood count, to look for clotting tendencies, 
and also to measure cholesterol and blood fat levels.
All infonnation obtained is treated in the strictest confidence, your GP will be informed 
of your results, and (if you wish) we will also inform you of the test results.
Note: Please do not have any breakfast on the morning of your visit, since some of the 
blood test results will be affected by intake of food.
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APPENDIX 3 
PARTICIPANT CONSENT FORM
FULL NAME.......
DATE OF BERTH 
ADDRESS
TELEPHONE Daytime ..................... Evening....................................................
NAME AND ADDRESS OF FAMILY DOCTOR
TO BE COMPLETED BY THE PARTICIPANT
Have you read the Participant Information Sheet? Yes □  No □
Have you had the opportimity to ask questions and discuss this study? Yes □  No □
Have you received satisfactory answers to all your questions? Yes O No □
Have you received enough information about the study? Yes O No O
You are free to withdraw from the study ♦  at any time ♦  without having to give a 
reason
Do you agree to take part in this study? Yes O No □
Do you agree to undergo a blood test to investigate your clotting factors? Yes □  NoO 
Do you agree to this blood test being used to investigate genes for clotting? Yes ONo □  
Do you agree to the results of tests being sent to your GP? Yes □  No □
Signed ...................................................................................................  D ate ...................
Name in block letters
Signatur e of witness .............................................................................. Date
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APPENDIX 4
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